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SUMMARY 
Understanding the contributions of the ECM biophysical and biochemical properties to 
epithelial cell responses has been a major goal for biomaterials scientists in order to 
engineer materials that can recapitulate ECM-mediated epithelial morphogenesis 
programs. Although 3D natural matrices have been found suitable for the study of many 
cellular processes, they are limited by lot-to-lot compositional and structural variability, 
inability to decouple mechanical and biochemical properties, and in some cases, their 
tumor-derived nature limits their clinical translational potential. Therefore, there is a 
significant need for a biomaterial matrix that can recapitulate epithelial morphogenetic 
programs while overcoming these limitations. 
This project aims to develop an engineered synthetic hydrogel matrix that presents 
independently-tunable basement membrane-like bioactivity and mechanical properties, 
and can support epithelial cell survival, proliferation, polarization, and assembly into 3D 
multicellular structures recapitulating different epithelial morphogenesis program. This 
synthetic material has the capacity to present adhesive peptides and protease-degradable 
crosslinks that support cell functions and promote cell engraftment in vivo. As part of this 
project, we have developed an engineered synthetic hydrogel platform that recapitulates 
the morphogenetic program of human pluripotent stem cell (hPSC)-derived intestinal 
organoids (HIOs), and has been established as a delivery vehicle for HIOs to mucosal 
intestinal wounds in mice. Furthermore, in order to prove the versatility of our hydrogel 
platform, we aim to engineer a synthetic hydrogel that recapitulates the mouse inner 
medullary collecting duct (IMCD) cell morphogenetic program. We hypothesize that these 
 xiv 
engineered hydrogels will be superior to naturally-derived materials by supporting these 
different epithelial morphogenetic programs while overcoming the imitations of natural 
and other synthetic materials. This synthetic hydrogel technology is significant as it allows 
the study of the independent contributions of ECM properties to different epithelial 
morphogenetic programs, and will form a basis for the adaptation to in vitro generation and 






CHAPTER 1. INTRODUCTION AND SPECIFIC AIMS 
1.1 Introduction 
Cell-extracellular matrix (ECM) interactions transduce mechanical and 
biochemical signals that regulate epithelial morphogenesis1-3. Understanding these 
interactions has been a major goal for biomaterials scientists in order to engineer materials 
that can recapitulate complex ECM-mediated cellular responses4. Bissell, Mostov and 
others have pioneered the use of 3D collagen and laminin (i.e., Matrigel™) gels in 
organotypic cultures that recreate the epithelial morphogenetic developmental programs 
observed in the organism5-7. Although 3D natural matrices have been found suitable for the 
study of many cellular processes, they are limited by lot-to-lot compositional and structural 
variability8 which decreases their reliability. Additionally, these matrices are limited by the 
inability to decouple mechanical and biochemical properties. Furthermore, as Matrigel™ 
is a tumor-derived matrix, its clinical translational potential is limited for regenerative 
medicine applications. Therefore, our lab has developed an engineered synthetic hydrogel 
matrix that presents independently-tunable basement membrane-like bioactivity and 
mechanical properties, and can support epithelial cell survival, proliferation, polarization, 
and assembly into 3D multicellular structures recapitulating the epithelial morphogenesis 
program9. These engineered polymer networks are based on a four-arm poly(ethylene 
glycol) (PEG) macromer with maleimide groups at each terminus (PEG-4MAL), and have 
the capacity to present adhesive peptides, protease-degradable cross-links, and growth 
factors that support cell functions and promote cell engraftment and tissue repair in vivo 10-
14.  Importantly, PEG-4MAL hydrogels exhibit high cytocompatibility, and minimal 
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toxicity and inflammation in vivo while offering significant advantages due to its well-
defined structure, stoichiometric incorporation of biofunctional groups, and tunable 
reaction time scales for in situ gelation for in vivo applications10,11. These engineered, 
synthetic materials offer a highly significant and disruptive opportunity to establish 
supportive microenvironments for different epithelial multicellular systems and robust 
delivery vehicles for in vivo applications. 
The objective of my project is to develop an engineered PEG-4MAL hydrogel 
platform with independently tunable physicochemical properties that can recapitulate 
different epithelial morphogenesis programs and serves as a delivery vehicle for 
regenerative medicine applications. This synthetic hydrogel platform will be engineered to 
recapitulate the morphogenetic program of human pluripotent stem cell (hPSC)-derived 
intestinal organoids (HIOs) and mouse inner medullary collecting duct (IMCD) cells. 
Additionally, the engineered hydrogel will be established as a delivery vehicle for HIOs to 
mucosal intestinal wounds in mice. I hypothesize that these engineered hydrogels will be 
superior to naturally-derived materials by supporting these different epithelial 
morphogenetic programs while overcoming the imitations of natural and other synthetic 
materials. This synthetic hydrogel technology is significant as it allows the study of the 
independent contributions of ECM properties to different epithelial morphogenetic 
programs, and will form a basis for the adaptation to in vitro generation and in vivo delivery 
of human PSC-derived organoids for regenerative medicine. The objective of the project 
will be achieved through the following specific aims: 
1.2 Specific Aim 1 
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Engineer a PEG-4MAL hydrogel that supports the generation of hPSC-derived 
intestinal organoids and serves as an injectable vehicle via colonoscope resulting in 
HIOs survival and engraftment into healing colonic wounds in mice. 
We will engineer a completely synthetic hydrogel that supports in vitro generation of 
intestinal organoids from hPSC-derived spheroids without the use of Matrigel™. We will 
study the contributions of the mechanical and biochemical properties of the synthetic ECM 
to intestinal organoid formation to identify an optimal formulation that supports intestinal 
spheroid survival, expansion and epithelial differentiation into HIOs and differentiation 
into mature intestinal tissue in vivo to similar levels as Matrigel™. We will also inject 
hydrogel liquid precursors and HIOs to murine intestinal mucosal wounds using a murine 
colonoscope in order to establish the use of the engineered hydrogel as a delivery vehicle 
for HIOs. This study will demonstrate that the modular nature of this hydrogel platform 
allows for the adaptation to in vitro generation and in vivo delivery of hPSC-derived 
intestinal organoids for regenerative medicine. 
1.3 Specific Aim 2 
Engineer a PEG-4MAL hydrogel that can recapitulate the tubulogenesis program of 
murine inner medullary collecting duct cells. 
We will engineer a PEG-4MAL hydrogel system that supports in vitro development of a 
tubular epithelial system using murine inner medullary collecting duct cells without the use 
of type I collagen gels. We will study the contributions of the biophysical and biochemical 
properties of the synthetic ECM to epithelial tubular system formation to identify an 
optimal formulation that supports epithelial cell survival, proliferation, polarization, and 
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assembly into 3D tubular structures to similar levels as type I collagen gels. This study will 
reveal the independent contributions of the physicochemical matrix properties to in vitro 
recapitulation of tubular epithelial morphological programs validating the modular nature 
of this hydrogel platform. 
1.4 Significance and Innovation 
The proposed project is innovative as it will use a synthetic material that overcomes 
the major limitations of naturally-derived materials by allowing the study of the 
independent contributions of ECM properties to different epithelial morphogenetic 
programs. Additionally, it will form a basis for the development of HIO-based therapies to 
treat gastrointestinal diseases in humans involving intestinal epithelial wounds (e.g., 
intestinal bowel disease, IBD), and for the adaptation to in vitro generation and in vivo 




CHAPTER 2. LITERATURE REVIEW1 
Synthetic Hydrogels Mimicking Basement Membrane Matrices to 
Promote Cell-Matrix Interactions1 
Naturally-derived materials have been extensively used as 3D cellular matrices as 
their inherent bioactivity makes them suitable for the study of many cellular processes. 
Nevertheless, lot-to-lot variability, inability to decouple biochemical and biophysical 
properties and, in some types, their tumor-derived nature limits their translational potential 
and reliability. One innovative approach to overcome these limitations has focused on 
incorporating bioactivity into cytocompatible, synthetic hydrogels that present tunable 
physicochemical properties. Incorporation of adhesive peptides, protease-degradable 
crosslinkers and growth factor binding domains to the polymer backbone are the most 
successful approaches to promote bioactivity in synthetic hydrogel matrices in order to 
recapitulate epithelial morphogenetic programs. Furthermore, the tunable physicochemical 
properties of these materials can be exploited to study the separate contributions of 
biochemical and biophysical matrix properties to different epithelial cellular processes. 
2.1 Basement Membrane-like Natural 3D Matrices 
In an attempt to create materials that mimic the native BM environment, matrices 
consisting of extracts or purified proteins (e.g. Matrigel™, type I collagen) have been 
developed. These 3D natural matrices have been used for a wide range of studies to model 
                                                 
1 Adapted from Cruz-Acuña, R. & García, A. J. Synthetic hydrogels mimicking basement membrane matrices 
to promote cell-matrix interactions. Matrix Biology, DOI: http://dx.doi.org/10.1016/j.matbio.2016.06.002 
(2016). 
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epithelial cell migration15, cancer invasion16 and metastasis17, as well as many epithelial 
morphogenetic programs18,19 due to their inherent bioactivity. The characteristics of some 
of these materials are highlighted below. 
2.1.1 Matrigel™ 
Matrigel™ is the commercial name for a BM extract secreted by Engelbrecht-
Holm-Swarm (EHS) mouse sarcoma cells. Matrigel™ is a complex mixture of over 1,000 
proteins8. It primarily consists of type IV collagen, laminin and nidogen, which makes it 
the most BM-like natural matrix model8,20. Epithelial morphogenesis21 and oncogenesis22, 
as well as intestinal organoid generation23-25 are current major areas that involve 3D 
cultures in Matrigel™. A study by Sato et al (2009)26 exemplifies the potential of 
Matrigel™ by establishing a 3D culture condition that generates intestinal crypt organoids 
from single intestinal stem cells in the absence of a cellular niche. After 4 days of 
encapsulation in Matrigel™, and supplemented with soluble proteins essential for crypt 
proliferation (R-spondin 1 and epidermal growth factor) and expansion (Noggin), the 
resulting multi-cellular structures comprise approximately 100 cells, which is consistent 
with the 12-hour cell cycle of proliferative crypt cells. Additionally, the presence of stem 
cells at the crypt bottom as well as four major differentiated epithelial cell types are present, 
demonstrating the ability of Matrigel™ to support intestinal epithelial expansion 
reminiscent of normal gut25. 
2.1.2 Laminin 
Laminins are highly biologically active molecules that can act as strong adhesive 
substrates for many cell types, and have been found to promote cell adhesion, migration, 
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protease activity, proliferation, tumor growth, angiogenesis, and metastasis27-29. Among 
the more of a dozen laminin isoforms, laminin-111 (also known as laminin-1; composed 
of α1-, β1-, and γ1-chains) is the most widely used for 2D and 3D culture systems as it can 
be isolated from EHS mouse tumors and it is commercially available27,30. The use of 
laminin-111 as a culture substrate has helped identify specific peptide motifs that promote 
malignant phenotypes by increasing tumor adhesion and migration, as well as tumor cell 
metastasis through induction of protease production28,30,31. Although laminin-111 is the 
most prominent and studied form of laminin, studies have provided insights into the 
importance of other laminin isoforms in the morphogenesis of different epithelial organs32-
34. 
2.1.3 Other Naturally-derived 3D Matrices 
Other naturally derived materials that have been used as cellular matrices include 
fibrin, alginate and hyaluronic acid gels. Fibrin gels, which are products of the 
polymerization of fibrinogen by the proteolytic activity of thrombin, started as one of the 
first biomaterials used to prevent bleeding and promote wound healing35, and transitioned 
to a variety of biomedical applications including islet transplantation36. Alginate and 
hyaluronic acid gels, which are derived from marine brown algae and vertebrate connective 
tissues, respectively37, are polysaccharides that have been extensively used as biomaterials 
for controlled release of drugs and tissue engineering applications38-40.  
2.2 Limitations of Natural Matrices 
 Although 3D natural matrices have been found suitable for the study of many 
cellular processes, they are limited by lot-to-lot compositional and structural variability8 
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which decrease their reliability. Additionally, these matrices are limited by the inability to 
decouple mechanical and biochemical properties. For instance, a common approach to vary 
the mechanical properties is to change the bulk concentration (e.g., increase matrix 
density). However, these changes in bulk concentration inevitably alter other matrix 
properties, such as adhesive ligand density and fiber density/structure. Furthermore, as 
Matrigel™ is a tumor-derived matrix, its clinical translational potential is limited for 
regenerative medicine applications. For these reasons, approaches have been pursued to 
overcome these limitations, including the combination of purified natural BM proteins with 
biocompatible synthetic hydrogels that exhibit defined mechanical properties41,42. 
However, although these materials have decoupled mechanical and biochemical properties, 
they still have limited translational potential. Therefore, as the field of biomaterials 
continues to advance, novel engineered synthetic hydrogel matrices that present 
independently-tunable BM-like bioactivity and mechanical properties have been 
developed, overcoming each of the aforementioned limitations of natural matrices. 
2.3 Synthetic Hydrogel Matrices 
 Hydrogels are water-swollen crosslinked polymer networks that can be considered 
synthetic equivalents of ECM matrices. Commonly used hydrogel polymers for biomedical 
applications include poly(acrylic acid) (PAA), poly(ethylene glycol) (PEG), poly(vinyl 
alcohol) (PVA), polyacrylamide (PAAm), and polypeptides43. These mesh-like structures 
are held together by either covalent crosslinks or non-covalent interactions that include 
ionic interactions, hydrogen bonds, affinity and hydrophobic interactions, polymer 
crystallites, physical entanglements, or a combination of the above44. 
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2.3.1 Physical Properties of Hydrogels 
Hydrogel stiffness and swelling behavior are two important physical characteristics 
that are inversely related and are primarily controlled by polymer density45,46. The swelling 
behavior of hydrogels involves a swelling force produced by the thermodynamic 
compatibility of the polymer chains and water, which is counterbalanced by the retractive 
forces exerted by its crosslinks44,45. Swelling equilibrium is reached when these two forces 
are equal44. Consequently, a hydrogel with high (low) polymer density has a greater 
(smaller) number of crosslinks that cause increased (decreased) retractive forces that will 
result in less (more) swelling. Moreover, an opposite effect is followed in hydrogel 
stiffness, as polymer density is proportional to the matrix stiffness; a high polymer density 
would produce a denser (thus, stiffer) polymer network. Hydrogel elastic modulus is an 
important physical parameter to consider in the design of a synthetic cellular matrix as 
many studies demonstrate matrix stiffness-dependent cellular responses, such as extent of 
cell migration and differentiation47,48. 
2.3.2 Synthesis of Hydrogels 
Among several methods to produce synthetic hydrogels matrices, photo-
polymerization and chemical reaction crosslinking stand out as two of the most widely 
used for biomedical applications43,49. Photo-polymerization involves the crosslinking of 
two water-soluble polymers (Fig. 1a), or copolymerization between one or more monomers 
and one multi-functional monomer (Fig. 1b), via photo-ionization of the monomers using 
light, often in the UV range. The high reactivity of the photo-ionized polymer components 
induces crosslinking reactions that produce a crosslinked network. As the polymerization 
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is light-dependent, this technique grants in situ spatiotemporal control over the mechanical 
properties of the hydrogel and presentation of incorporated ligands43,50-52. 
 
Figure 1: Synthesis methods of engineered synthetic hydrogels. Photo-polymerization of 
two water-soluble polymers (A) and copolymerization of one monomer and one multi-
functional monomer (B) via covalent reaction after UV irradiation. (C) Direct chemical 
reaction of a branched polymer with a di-functional crosslinking agent. (D) Electrostatic 
interactions of an anionic polymer with divalent cations yields an “ionotropic” hydrogel. 
(E) Encapsulated cells in an engineered biofunctionalized hydrogel exhibiting adhesive 
ligand, growth factor-binding domain and MMP-degradable crosslinks. 
Chemical reaction crosslinking involves a direct chemical reaction between linear 
or branched polymer macromolecules (macromers) with a di-functional or multi-functional 
crosslinking agent. Each agent, which has a smaller molecular weight, crosslinks two or 
more macromers together forming a mesh-like structured hydrogel49 (Fig. 1c). Examples 
of chemical reactions used to produce hydrogels are chemical ligation53, click chemistry54 
and Michael-type addition reaction10. 
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These two general hydrogel synthesis methods have been widely used for 
generating artificial 3D cellular matrices as they allow easy incorporation of BM-like 
biochemical properties, which will be discussed in the next section. Although these 
synthesis techniques are based on covalently crosslinking the synthetic hydrogel 
constituents, there are other synthesis methods that involve crosslinking by non-covalent 
interactions which are common in naturally-derived hydrogels, such as alginate 
“ionotropic” hydrogels which are formed based on electrostatic interactions49 (Figure 1d).  
2.4 Incorporation of BM-like Properties to Synthetic Hydrogels 
 The BM contains key biophysical and biochemical characteristics that are essential 
for epithelial and endothelial cell attachment and viability as well as numerous cellular 
processes that include proliferation, differentiation, and migration. These cellular processes 
are primarily mediated by cell-matrix interactions via integrins, the ability of cells to 
remodel their supporting matrix via degradation of their microenvironment, and by 
presentation of growth factors55. Consequently, in order to incorporate bioactivity into 
artificial hydrogel matrices, successful approaches have focused on incorporating bioactive 
peptides derived from natural ECM. Three common themes explored in biofunctional 
hydrogels are (1) cell adhesive peptides, (2) protease-degradable crosslinkers, and (3) 
growth factor-binding domains in order to mimic native cell-BM interactions (Fig. 1e). 
2.4.1 Cell Adhesive Peptides 
 Integrin binding to short peptide sequences present in BM proteins such as collagen 
and laminin provides cellular attachment and triggers signals that direct cell function, cell-
cycle progression and expression of differentiated phenotypes56-59. Therefore, 
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incorporating biofunctional short peptide sequences into 3D artificial hydrogel systems has 
been an effective method to promote integrin-mediated cellular functions. These peptide 
motifs have the advantage of being relatively stable, and can be covalently tethered to the 
hydrogel polymer backbone at tunable densities via integration of reactive groups, yielding 
a biofunctionalized hydrogel43. The most widely used cell-adhesive motif is the short 
peptide arginine-glycine-aspartic acid (RGD); this oligopeptide was originally identified 
in fibronectin but is also present in many other ECM proteins including laminin and 
collagen60.  Presentation of RGD on synthetic matrices supports cell adhesion by targeting 
integrins, such as αvβ3. Many studies have demonstrated successful BM-like bioactivity of 
RGD-functionalized hydrogels, as compared to non-functionalized matrices, by directing 
essential cellular processes such as attachment and spreading61, migration and invasion62,63, 
and stem cell support64 and differentiation65. Furthermore, other peptides like IKVAV and 
YIGSR, which are derived from laminin, can also be incorporated into hydrogels together 
with RGD to orchestrate ligand density-dependent signal presentation independently of the 
mechanical characteristics of the matrix65,66. This demonstrates the potential of engineered 
hydrogels as matrices that can elucidate tunable biochemical signals that direct complex 
cellular processes via presentation of cell adhesion peptides. 
2.4.2 Protease-Degradable Crosslinkers 
 The capacity of cells to modify their microenvironment via matrix degradation is 
essential for their ability to migrate and proliferate, as well as for tissue remodeling and 
homeostasis55. ECM remodeling involves degradation and modification of its protein 
components, most significantly by cell-secreted or membrane-bound matrix 
metalloproteinases (MMPs)67. Therefore, crosslinking hydrogel matrices with MMP-
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cleavable peptides has been a widely used strategy to allow for cell-directed modifications 
of the matrix biophysical characteristics. These short peptide sequences are derived from 
ECM proteins, such as type I or type IV collagen, and incorporation into synthetic hydrogel 
matrices conveys sensitivity to MMP-dependent degradation47,68. Moreover, studies show 
that mutations to, or combinations of, different MMP-sensitive crosslinking peptides can 
yield hydrogels with different degradability rates that result in variations of cellular 
responses within the hydrogel, such as extent of cell invasion47 and determination of stem 
cell fate48,69. This demonstrates that artificial hydrogel matrices with tunable degradability 
rates present BM-like bioactivity that can direct a wide range of cellular responses 
independent of their cell adhesive peptide density.  
2.4.3 Growth Factor-binding Domains 
 The BM hosts a wide variety of signaling molecules such as growth factors (GFs), 
which reside in the matrix by non-covalent interactions with heparan sulfate proteoglycans 
such as perlecan and other minor BM components (agrin and type XVIII collagen)70,71. 
GFs play significant roles in tissue development by eliciting a variety of essential cellular 
responses such as cell proliferation, stem cell differentiation, and vascular and organ 
morphogenesis72. Therefore, presentation of specific GF types and densities to cells 
through the use of artificial hydrogel matrices has been an effective approach to orchestrate 
desired cellular responses. The traditional method for GF incorporation into hydrogels is 
direct encapsulation, which involves physical entrapment of GFs within the matrix which 
will be released as the hydrogel degrades and/or will diffuse out of the hydrogel network73. 
Nevertheless, as this method may not provide long-term control over GF presentation, 
another approach has been to covalently tether GFs to the hydrogel backbone70,74. 
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However, as covalent linkage may compromise GF activity by alterations to its 
conformation or masking its active sites, strategies focus on incorporating GF-binding 
domains into hydrogel matrices by covalently tethering heparan sulfate-containing 
molecules to the polymer backbone that interact with GFs75-77. This method, compared to 
previous approaches, has gained popularity as it mimics native BM-GF non-covalent 
interactions within artificial hydrogel matrices. Consequently, investigations have 
demonstrated inherent GF-directed cellular responses via presentation of GF-binding 
domains within synthetic hydrogels, such as in vivo neovascularization78,79 and wound 
healing75. 
2.5 Exemplary Applications of BM-mimicking Hydrogels 
As the fields of cell and matrix biology progress, our understanding of what 
biological cues are essential for specific cellular processes becomes clearer, and thus, more 
robust synthetic hydrogels that present these essential biological signals have been 
engineered. In order to construct such materials, it is critical to understand how changes in 
the chemical and physical characteristics of hydrogels translate into changes in the local 
microenvironment of encapsulated cells. The establishment of an artificial hydrogel 
microenvironment that directs epithelial morphogenesis, controls cell fate, and provides 
insights into cancer progression are among the most recent advances in the field of 
biomaterials, and various studies are highlighted below. 
2.5.1 Epithelial Morphogenesis 
 Epithelial morphogenesis is part of the organogenesis program of multicellular 
organisms where the epithelia form transient structures, such as tubules and hollow 
 15 
spherical systems (cysts), that further develop into more complex organs80. During this 
process, epithelial cells establish tight junctions among neighboring epithelial cells through 
their lateral membranes, and connections to their supporting BM via integrin receptors in 
their basal membranes81, which contribute to their distinctive cellular polarity21,81. Studies 
using 3D collagen and laminin gel cultures have demonstrated that the epithelial 
morphogenesis developmental program is regulated by biochemical and mechanical 
signals that result from cell-BM interactions18,81,82. In these studies, single-cell 
encapsulation of epithelial cells, such as MDCK cells, results in cell proliferation into a 
multicellular aggregate and further development of cysts composed of a polarized epithelial 
monolayer that recreates the morphogenesis of epithelial organs83. Although these natural 
matrices have been able to recapitulate the epithelial morphogenesis program of MDCK 
cells, they do not offer the capacity to study individual contributions of the mechanical and 
biochemical properties of the ECM towards epithelial morphogenesis. Therefore, 
Enemchukwu et al (2016)9 established an engineered ECM-mimetic PEG hydrogel system 
with independent control over ligand density and presentation, proteolytic degradation and 
mechanical properties to independently study the effects of ECM biochemical and 
biophysical properties on MDCK cell morphogenesis. In this study, normal cyst growth, 
polarization, and lumen formation were restricted to a narrow range of hydrogel elasticity 
that was controlled by the polymer density. Additionally, RGD density dramatically 
regulated apicobasal polarity and lumenogenesis independently of cell proliferation, and a 
threshold level of MMP-directed hydrogel degradation rate was required to regulate these 
critical epithelial characteristics. This study offers new insights into how ECM biochemical 
and biophysical properties independently regulate epithelial morphogenetic behaviors, as 
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well as present a platform technology that could potentially be adopted in developmental 
cell and tumor biology fields to study ECM-directed processes. 
2.5.2 3D iPSCs Generation 
 Since the discovery of induced pluripotent stem cells (iPSCs), reprogramming of 
somatic cells has been considered a multi-step process that is initiated by cytoskeletal and 
epigenetic alterations84-86. Some of these alterations are related to effects of the ECM on 
cells, for example, iPSC generation can be influenced by biophysical parameters in 2D 
culture87. In order to better understand the role of the microenvironment on somatic-cell 
reprogramming, a synthetic 3D ECM-like hydrogel culture system that supports the 
initiation of reprogramming was developed by Lutolf86. These PEG hydrogels allow for 
precise control of the physiochemical characteristics of the cellular microenvironment 
which is not possible in 2D culture. In order to take full advantage of the tunable nature of 
this hydrogel, a high-throughput imaging system was used to detect pluripotency levels as 
a function of hydrogel stiffness, susceptibility to MMP degradation, and functionalization 
with different proteins previously shown to play a role in regulating pluripotency. This 
analysis yielded an engineered 3D PEG hydrogel that demonstrated a 2.5-fold higher 
reprogramming efficiency of human fibroblasts into iPSCs as compared to 2D culture. The 
accelerated reprogramming was attributed to hydrogel matrix selection of colony-forming 
iPSCs by limiting proliferation of non-colony-forming cells, and to the pronounced 
morphological changes that may cause the key events for the initiation of iPSC generation. 
These findings provide the first proof of principle for 3D reprogramming in synthetic 
matrices, and demonstrate the capacity of an engineered ECM-like hydrogel system to 
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reveal the influence of the physiochemical characteristics of the cellular microenvironment 
in cell fate regulation. 
2.6 Outlook for BM-like Synthetic Hydrogel Matrices 
Although the studies discussed in here have developed novel artificial hydrogel 
matrices that present BM-like properties, several challenges need to be addressed in order 
to continue engineering synthetic matrices that recapitulate and direct complex cellular 
processes. For instance, there is a need for hydrogels that can recapitulate the in vivo 
microenvironment by presentation of multiple adhesive ligand types at specific densities 
that can orchestrate complex cellular responses. Such artificial matrix designs are 
important for the support of complex cellular systems (e.g. primary and stem cells) that 
still represent a challenge due to their increased sensitivity, and to further direct innate 
cellular functions. Furthermore, as different studies have demonstrated successful culture 
of complex cellular systems using Matrigel™, future developments of BM-like synthetic 
hydrogels should move towards designing hydrogels that recapitulate mechanical and 
structural (e.g., fibrillar structure) properties of Matrigel™ and collagen gels. 
Consequently, designing artificial matrices that present combinations of biochemical 
signals by functionalization with multiple adhesive ligand types, and possess biophysical 
characteristics of Matrigel™, may lead to hydrogels that reiterate the in vivo 
microenvironment of complex cellular systems and can, thus, further expand their 
application as cell-delivery vehicles for in vivo studies. Therefore, as new ways of 
integrating bioactivity into hydrogel matrices are designed, these novel engineered 
synthetic materials will continue to offer new developments in regenerative medicine and 
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tissue engineering fields, and promise innovative therapeutic options that naturally derived 
materials cannot provide. 
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CHAPTER 3. SYNTHETIC HYDROGELS FOR HUMAN 
INTESTINAL ORGANOID GENERATION AND COLONIC 
WOUND REPAIR2 
3.1 Abstract 
In vitro differentiation of human intestinal organoids (HIOs) from pluripotent stem 
cells is an unparalleled system for creating complex, multi-cellular 3D structures capable 
of giving rise to tissue analogous to native human tissue. Current methods for generating 
HIOs rely on growth in an undefined tumor-derived extracellular matrix (ECM), which 
severely limits use of organoid technologies for regenerative and translational medicine. 
Here, we developed a fully defined, synthetic hydrogel based on a four-armed, maleimide-
terminated poly(ethylene glycol) macromer that supports robust and highly reproducible 
in vitro growth and expansion of HIOs such that 3D structures are never embedded in 
tumor-derived ECM. We also demonstrate that the hydrogel serves as an injectable HIO 
vehicle that can be delivered into injured intestinal mucosa resulting in HIO engraftment 
and improved colonic wound repair. Together, these studies show proof-of-concept that 
HIOs may be used therapeutically to treat intestinal injury. 
3.2 Introduction 
Human pluripotent stem cells (hPSCs), such as embryonic stem cells (ESCs)88 and 
induced pluripotent stem cells (iPSCs)89, are important cell sources for regenerative 
                                                 
2 Adapted from Cruz-Acuña, R. and Quirós, M. et al. Synthetic hydrogels for human intestinal organoid 
generation and colonic wound repair. Nature Cell Biology, DOI: 10.1038/ncb3632 (2017). 
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therapies and modeling of human diseases90-92. In vitro generation of human organoids 
from hPSCs offers unparalleled strategies for generating multi-cellular 3D structures 
recapitulating important features of epithelial and mesenchymal tissues24,25,93,94. For 
example, human intestinal organoid (HIO) technology provides a powerful platform for 
functional modeling and repair of genetic defects in human intestinal development95,96 and 
the establishment of chronic disease models, such as inflammatory bowel disease97.  
In order to generate HIOs, hPSCs were cultured and differentiated using growth 
factors in a MatrigelTM-coated substrate, giving rise to 3D intestinal spheroids which were 
collected and encapsulated within MatrigelTM for expansion into HIOs98. MatrigelTM is a 
heterogeneous, complex mixture of ECM proteins, proteoglycans, and growth factors 
secreted by Engelbreth-Holm-Swarm mouse sarcoma cells99, which is required for 3D 
growth and expansion of HIOs. However, MatrigelTM suffers from lot-to-lot compositional 
and structural variability and, importantly, this tumor-derived matrix has limited clinical 
translational potential100. Indeed, a synthetic alternative to MatrigelTM that supports murine 
intestinal stem cell expansion and organoid formation has been recently reported100. 
Here, we describe a completely synthetic hydrogel that supports in vitro generation 
of intestinal organoids from human ESC- and iPSC-derived 3D spheroids without 
MatrigelTM encapsulation and promotes their engraftment and healing of murine colonic 
mucosal wounds. Hydrogel mechanical properties and adhesive ligand type were key 
parameters in engineering a synthetic ECM mimic that supported HIO viability, expansion 
and development. Additionally, this synthetic hydrogel served as an injectable vehicle to 
deliver HIOs to intestinal wounds via a colonoscope resulting in organoid survival, 
engraftment, and wound repair. The modular design of this synthetic matrix and ability to 
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deliver via endoscopic techniques support the translational potential of this delivery 
platform for regenerative medicine and overcomes limitations associated with the use of 
MatrigelTM for hPSC-based organoid technologies. 
3.3 Results 
3.3.1 Engineered hydrogels support HIO viability 
We selected a hydrogel platform based on a four-arm poly(ethylene glycol) (PEG) 
macromer with maleimide groups at each terminus (PEG-4MAL) (Fig. 2a), which exhibits 
high cytocompatibility and minimal toxicity and inflammation in vivo10,11. Moreover, this 
hydrogel system offers significant advantages due to its well-defined structure, 
stoichiometric incorporation of biofunctional groups, and tunable reaction time scales for 
in situ gelation for in vivo applications10,11.  
PEG-4MAL macromers were functionalized with adhesive peptides and 
crosslinked in the presence of cells to generate PEG-4MAL hydrogels (Fig. 2a,b). The 
mechanical properties of the hydrogel were tuned by varying polymer density (Fig. 2c,d). 
We explored hydrogel formulations that supported the viability of ESC-derived HIOs that 
were first generated in MatrigelTM. After HIOs were grown in MatrigelTM, they were 
retrieved and encapsulated in PEG-4MAL hydrogel formulations (Fig. 2e). Because ECM 
mechanical properties influence epithelial cell behaviors9, we investigated the influence of 
hydrogel polymer density (3.5-6.0% wt/vol), which controls hydrogel mechanical 
properties (Fig. 2c,d), on HIO viability at day 7 post-encapsulation (Fig. 3a). For reference, 
the mechanical properties of Matrigel™ (G’ = 78 Pa, G’’ = 5.8 Pa) are in the range of the 
3.5-4.0% PEG-4MAL formulations. These synthetic hydrogels were engineered to present 
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a constant 2.0 mM RGD adhesive peptide (GRGDSPC) density and crosslinked with the 
protease-degradable peptide GPQ-W (GCRDGPQGIWGQDRCG). This adhesive peptide 
type and density were chosen as they have been shown to support high epithelial cell 
viability and cyst formation in PEG-4MAL hydrogels9. The protease-degradable 
crosslinking peptide is necessary for cell-dependent matrix remodeling, cell migration and 
growth9,86. HIOs embedded in 3.5% and 4.0% PEG-4MAL gels grew as cysts with an 
epithelium and central lumen, and maintained high viability for at least 7 d in culture 
comparable with growth and viability of HIOs in MatrigelTM (Fig. 3a). Quantification of 
organoid viability area demonstrated no significant differences between HIOs embedded 
in 3.5% or 4.0% PEG-4MAL gels and HIOs in Matrigel (Fig. 3b). In contrast, organoids 
encapsulated in 5.0% or 6.0% PEG-4MAL hydrogels exhibited a significantly reduced 
viability at day 7 after encapsulation as compared to HIOs embedded in 3.5%, 4.0% PEG-
4MAL gels or Matrigel (Fig. 3a,b). These results suggest polymer density-dependent 
effects on HIO survival within PEG-4MAL hydrogels. Although 3.5% PEG-4MAL 
hydrogels supported high HIO viability, this formulation was less mechanically stable 
compared to 4.0% PEG-4MAL hydrogels by 7 days in culture. We therefore selected 4.0% 
PEG-MAL hydrogels for subsequent studies. 
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Figure 2: PEG-4MAL hydrogel preparation and mechanical properties. (a) PEG-
4MAL macromers are conjugated with thiol-containing adhesive peptide to produce a 
functionalized PEG-4MAL macromer, which is then crosslinked in the presence of HIOs 
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using protease-cleavable peptides containing terminal cysteines to form a (b) hydrogel 
network. (c,d) Relationship between polymer density (wt%) and (c) storage modulus or (d) 
loss modulus (mean ± SEM; n = 10 independently prepared hydrogels per condition). (e) 
Schematic of spheroid development into HIOs within MatrigelTM and further growth within 
PEG-4MAL hydrogel. (f) Schematic of spheroid development into HIOs within hydrogel. 
(c,d) Graphs are representative of one experiment.  
 
 
Figure 3: PEG-4MAL polymer density and adhesive ligand type control HIO viability. (a) 
Transmitted light and fluorescence microscopy images of HIOs cultured in PEG-4MAL 
hydrogels of different polymer density or MatrigelTM. HIO viability was assessed at 7 d 
after encapsulation. Bar, 500 μm. (b) Percentage of total organoid area stained for live or 
dead (mean ± SEM) after 7 d of encapsulation (n = 5 organoids analyzed for all groups, 
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except n = 6 organoids analyzed for 4.0% group). (c) Transmitted light and fluorescence 
microscopy images of HIOs cultured in 4.0% PEG-4MAL hydrogels functionalized with 
different adhesive peptides or MatrigelTM. HIO viability was assessed at 7 d after 
encapsulation. Bar, 500 μm. (d) Percentage of total organoid area stained for live or dead 
(mean ± SEM) after 7 d of encapsulation (n = 5 organoids analyzed for all groups, except 
n = 6 organoids analyzed for AG73 and Matrigel groups). (b,d) One-way ANOVA with 
Tukey’s multiple comparisons test showed significant differences between (b) 4.0% PEG-
4MAL or MatrigelTM and 5.0 or 6.0% PEG-4MAL, and between (b) PEG-4MAL-RGD or 
MatrigelTM and PEG-4MAL-GFOGER or -IKVAV. (*P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001). (a-d) Three independent experiments were performed and data is 
presented for one of the experiments. All experiments performed with 6 PEG-
4MAL/MatrigelTM per experimental group. 
Interactions between adhesion receptors and ECM provide signals critical for cell 
survival, proliferation and differentiation101. Therefore, we examined whether the adhesive 
ligand type in the synthetic hydrogel impacts HIO viability. Organoids were embedded 
within PEG-4MAL formulations of 4.0% polymer density and constant GPQ-W 
crosslinking peptide density but with different cysteine-terminated adhesive peptides (all 
at 2.0 mM; Fig. 3c,d): RGD, laminin α1 chain-derived AG73 (CGGRKRLQVQLSIRT)102, 
type I collagen-mimetic triple helical GFOGER 
(GYGGGP(GPP)5GFOGER(GPP)5GPC)
103, and laminin α1 chain-derived IKVAV 
(CGGAASIKVAVSADR)30. Since the adhesive peptide-functionalized macromer 
building blocks of the hydrogel are symmetric and form a regular mesh structure that is 
fully swollen, the adhesive peptide is uniformly distributed throughout the hydrogel 
network within the ‘statistical average’ of the mesh size (30-40 nm). Furthermore, because 
of the small size of the PEG macromer arms and the swollen state of the gel, the mobility 
of the adhesive peptide is very limited and there is no effective clustering of the adhesive 
peptide9. Nevertheless, changes in adhesive peptide at the nanoscale cannot be completely 
ruled out. Organoids encapsulated in RGD-functionalized hydrogels maintained high 
viability for at least 7 d after encapsulation (Fig. 3c,d; Fig. 4a), similar to viability within 
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MatrigelTM. In contrast, organoids encapsulated in PEG-4MAL hydrogels functionalized 
with AG73, GFOGER or IKVAV showed reduced viability at 7 d post-encapsulation (Fig. 
3c,d). Adhesion to RGD was required for HIO viability as organoids encapsulated in 
hydrogels presenting an inactive scrambled peptide (RDG) showed reduced viability at 7 
d post-encapsulation (Fig. 4b). Finally, organoids exhibited low viability at 7 d post-
encapsulation in hydrogels crosslinked with non-degradable molecules (DTT), 
demonstrating that prolonged survival of HIO requires a degradable matrix (Fig. 4c). Taken 
together, these results identify an engineered hydrogel formulation (4.0% polymer density, 
2.0 mM RGD adhesive peptide, GPQ-W crosslinking peptide) that supports high viability 
for established HIOs, and which was used for all subsequent experiments. 
3.3.2 Engineered hydrogel supports HIO development 
We next examined HIO maintenance during culture in engineered hydrogels. Over 
several days in culture, established HIOs grew in size, changed shape, maintained a central 
lumen, and displayed epithelial budding at the interface with the hydrogel (Fig. 4d). 
Additionally, mesenchymal cells were observed migrating into the hydrogel, similar to 
HIOs maintained in MatrigelTM (Fig. 4d,e). To further characterize the intestinal epithelium 
of HIOs, we examined cell proliferation and apicobasal polarity in HIOs generated in 
MatrigelTM and those transferred to the engineered PEG-4MAL hydrogels. After 7 d in 
culture, HIOs stained positive for Ki67, indicating cell proliferation, demonstrated 
appropriate polarization of apical (EZRIN) and basolateral (β-CATENIN) proteins, and 
localization of an epithelial tight junction protein (ZO-1)104 (Fig. 4f,g). The staining 
patterns were similar when comparing HIOs maintained in PEG-4MAL hydrogel and 
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MatrigelTM (Fig. 4f,g), demonstrating that the engineered PEG-4MAL hydrogel robustly 
supports HIO maintenance. 
 
Figure 4: Engineered PEG-4MAL supports HIO development. (a) Transmitted light and 
fluorescence microscopy images of HIOs cultured in 4.0% PEG-4MAL hydrogels 
functionalized with (a) RGD, (b) inactive, scrambled RDG peptide, or (c) non-degradable 
crosslinker (DTT). HIO viability was assessed at 7 d after encapsulation. (d,e) Transmitted 
light microscopy images of MatrigelTM-generated HIOs cultured within (d) 4.0% PEG-
4MAL-RGD hydrogel or (e) MatrigelTM over time. Bars, 500 μm. (f,g) Fluorescence 
microscopy images of a HIO at 7 d after encapsulation in 4.0% PEG-4MAL-RGD hydrogel 
or MatrigelTM, and labeled for (f) β-CATENIN, proliferative cells (KI67), and (g) epithelial 
apical polarity (EZRIN) and tight junctions (ZO-1). DAPI, counterstain. “L” indicates HIO 
lumen. Bars, 100 μm. (a-g) Three independent experiments were performed and data is 
presented for one of the experiments. Experiments performed with (a-c) 4, (f,g) 6 or (d,e) 
12 PEG-4MAL/MatrigelTM per experimental group. 
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3.3.3 Engineered hydrogel generates HIOs from spheroids 
The use of MatrigelTM to generate HIOs is a fundamental roadblock to the clinical 
translation of organoid technologies. We therefore examined whether the engineered PEG-
4MAL hydrogel supports survival of hESC-derived intestinal spheroids and growth into 
HIOs without ever embedding in MatrigelTM. After 4-5 days of induction towards the 
intestinal lineage on a MatrigelTM-coated substrate, small 3D intestinal spheroids self-
assemble and bud off from the cultured monolayer losing contact with MatrigelTM. 
Detached, floating mCherry-expressing intestinal spheroids were collected from the media 
and encapsulated in PEG-4MAL hydrogels formulated over a range of polymer densities 
(3.5%-12.0%) (Fig. 2f) to examine a range of mechanical properties (Fig. 2c,d). All these 
hydrogels were engineered to present 2.0 mM RGD adhesive peptide and crosslinked with 
GPQ-W. Spheroids embedded in 3.5% and 4.0% PEG-4MAL maintained viability at 2 h 
after encapsulation and grew into larger structures reminiscent of organoids with high 
viability at 5 d after encapsulation (Fig. 5a). In contrast, spheroids encapsulated in 8.0% 
and 12.0% PEG-4MAL hydrogels displayed significantly lower viability at 2 h post-
encapsulation when compared to spheroids embedded in 3.5% or 4.0% PEG-4MAL (Fig. 
5a). Consistent results were observed between hESC- and hiPSC-derived spheroids (Fig. 
6). hiPSC-derived intestinal spheroids encapsulated in 4.0% PEG-4MAL grew into 
organoids with high viability at 5 d after encapsulation and developed over 3 weeks into 
HIOs similar to spheroids encapsulated in Matrigel™ (Fig. 6a,b). In contrast, hiPSC-
derived spheroids encapsulated in 8.0% PEG-4MAL hydrogels showed very low viability 
by 1 d post-encapsulation (Fig. 6c). 
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Figure 5: PEG-4MAL polymer density regulates HIO generation from intestinal spheroids 
in the absence of MatrigelTM embedding. (a) Transmitted light and fluorescence 
microscopy images of mCherry-spheroids cultured in PEG-4MAL hydrogels of different 
polymer density or MatrigelTM. Spheroids viability was assessed by Calcein-AM labeling 
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at 2 hr after encapsulation (day 0) and at day 5 for PEG-4MAL conditions, and at day 3 for 
MatrigelTM. Bar, 100 μm. Viability is quantified as percentage of total spheroid or 
organoid area stained for live or dead (mean ± SEM; n = 5 organoids analyzed per 
condition/time-point). One-way ANOVA with Tukey’s multiple comparisons test showed 
significant differences between 3.5% or 4.0% PEG-4MAL and 8.0% or 12.0% PEG-4MAL 
at Day 0 (****P < 0.0001). (b) HIO projected area and (c) Feret diameter normalized to 
Day 0 values at different time-points after encapsulation in 4.0% PEG-4MAL-RGD 
hydrogel (●) or MatrigelTM (■) (n = 6 organoids for PEG-4MAL and n = 4 organoids for 
MatrigelTM per time-point). Repeated measures two-way ANOVA showed no significant 
difference between matrix types (P > 0.05). Graph line represents the mean of the 
individual data points at each time-point. (d,e) Fluorescence microscopy images of a HIO 
at 21 d after encapsulation in 4.0% PEG-4MAL-RGD hydrogel or MatrigelTM and labeled 
for (d) β-CATENIN, proliferative cells (KI67), and (e) epithelial apical polarity (EZRIN) 
and tight junctions (ZO-1). DAPI, counterstain. “L” indicates HIO lumen. Bars, 100 μm. 
Three independent experiments were performed and data is presented for one of the 




Figure 6: PEG-4MAL hydrogel supports hiPSC-derived intestinal spheroid development 
into HIOs comparable to hESC-derived spheroids. (a) Transmitted light and fluorescence 
microscopy images of hiPSC-derived HIO generation within (a) 4.0% PEG-4MAL-RGD 
hydrogels, (b) MatrigelTM, or (c) 8.0% PEG-4MAL-RGD hydrogels. hiPSC-derived 
spheroid and HIO viability was assessed at different time-points after encapsulation. (d) 
 32 
Transmitted light microscopy images of hESC-derived HIO generation within 4.0% PEG-
4MAL-RGD hydrogels. (a,c,d) These organoids were never encapsulated within 
MatrigelTM. Black arrows show epithelial budding. Bars, 500 μm. Three independent 
experiments were performed and data is presented for one of the experiments. All 
experiments performed with 12 PEG-4MAL/MatrigelTM per experimental condition. 
The strong dependence of spheroid and HIO viability on hydrogel polymer density 
suggests that the mechanical properties of these synthetic matrices regulate organoid 
survival. However, varying polymer density also alters the mesh size for these networks 
which can impact diffusional properties of the hydrogel. It is not possible to uncouple 
mechanical properties from diffusional properties over the full range of polymer densities 
(3.5%-12.0%) examined in this study. However, we compared organoid viability and size 
in RGD-functionalized hydrogels from different macromer sizes (20 vs. 40 kDa) but 
different polymer densities (4.0% vs. 8.0%) and engineered to have equivalent crosslinking 
densities (Fig. 7a-c). These hydrogels exhibit different diffusive 
characteristics/permeability caused by the differences in macromer arm length but have 
equivalent mechanical properties due to equivalent crosslinking densities9. ESC-derived 
spheroids developed normally into HIOs after 5 days of encapsulation in either hydrogel 
formulation showing no differences in HIO viability (Fig. 7a,b), and no differences in 
projected area and longest distance between two points along the projected area (Feret 
diameter; Fig. 7c). These results suggest that polymer density-dependent spheroid survival 
and development into HIOs is related to hydrogel mechanical properties.  Furthermore, we 
evaluated the role of known mechanotransduction pathways on spheroid survival. 
Inhibition of nuclear translocation of yes-associated protein (YAP), which has been 
implicated in mechanostransduction and regulation of intestinal stem cell self-renewal100, 
using verteporfin resulted in significant cell death for spheroids encapsulated in PEG-
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4MAL hydrogels compared to vehicle control (Fig. 7d-f). Treatment with blebbistatin or 
Y-27632, which inhibit myosin II and Rho-associated kinase105,106, respectively, resulted 
in dose-dependent increases in apoptosis and spheroid death at 1 d post-encapsulation (Fig. 
7d-f). These results provide a preliminary indication that YAP and cellular contractility are 
important in the initial stages of human intestinal spheroid survival and development into 
HIOs. 
 
Figure 7: PEG-4MAL hydrogels with different macromer sizes and mediators of 
mechanotransduction are essential for hESC-derived spheroid survival. (a) Transmitted 
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light and fluorescence microscopy images of HIO generation within 20 kDa (4.0%) or 40 
kDa (8.0%) PEG-4MAL-RGD hydrogels. HIO viability was assessed at 5 d after 
encapsulation. (b) Percentage of total organoid area stained for live or dead (mean ± SEM) 
after 5 d of encapsulation (n = 6 organoids analyzed per condition). (c) HIO projected area 
and Feret diameter normalized to Day 0 values (mean ± SEM) after 5 d of encapsulation 
(n = 5 organoids analyzed per condition). (b,c) Unpaired two-tailed t-test with Welch’s 
correction showed no significant differences between HIO viability or HIO size parameters 
within 20 kDa (4.0%) and 40 kDa (8.0%) PEG-4MAL-RGD (P > 0.05). (d) Transmitted 
light and fluorescence microscopy images of spheroids cultured within 4.0% PEG-4MAL-
RGD hydrogels supplemented with (d) 10 µM or (e) 30 µM of verteporfin, Y-27632 or 
blebbistatin, or (f) DMSO (vehicle control). Spheroids death was assessed by annexin-V 
(apoptosis) and propidium iodide (dead) labeling at 1 d after encapsulation. Bars, 100 μm. 
One experiment was performed with 12 PEG-4MAL hydrogels per experimental condition.  
We next analyzed HIO generation from ESC-derived spheroids cultured within the 
engineered synthetic matrix (4.0% polymer density, 2.0 mM RGD, GPQ-W crosslinker). 
Intestinal spheroids cultured within PEG-4MAL hydrogels grew in size over 7 d as shown 
by a 2-fold increase in projected area (Fig. 5b) and 1.4-fold increase in Feret diameter (Fig. 
5c) as compared to the day of encapsulation (Day 0; Fig. 5b,c). There were no differences 
in spheroid area, diameter, or growth rates between spheroids cultured in PEG-4MAL 
hydrogels and MatrigelTM (Fig. 5b,c). Similar to our observations for established HIOs, 
spheroids changed shape during expansion and displayed epithelial budding at the interface 
with the hydrogel and cell outgrowths migrating into the hydrogel (Fig. 6d). During HIO 
development, spheroids cultured in PEG-4MAL hydrogels were passaged in a similar 
manner as previously described for Matrigel98,107. Immunostaining analyses at 21 d post-
encapsulation demonstrated that organoids generated in engineered PEG-4MAL hydrogels 
were proliferating as shown by Ki67 labeling, had polarized distribution of apical EZRIN 
and basolateral β-CATENIN, and expressed ZO-1 in the apical junctional complex (Fig. 
7d,e). These staining patterns were identical to organoids generated in MatrigelTM. 
Quantitative reverse transcription polymerase chain reaction (RT-qPCR) confirmed that 
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expression levels of pluripotency (OCT4), endoderm (FOXA2), and epithelial junction 
(ZO1, ECAD and CLDN2) markers in hydrogel-encapsulated spheroids were comparable 
to those embedded in MatrigelTM and had similar behaviors during early timepoints while 
developing into HIOs (Fig. 8). Finally, to test whether these synthetic matrices are suitable 
for the culture of other human organoids, we embedded human lung organoids 
(HLOs)108,109 in engineered PEG-4MAL hydrogels (Fig. 9). HLOs cultured in PEG-4MAL 
hydrogels maintained high viability 7 d after encapsulation (Fig. 9a), and demonstrated an 
organized lung epithelium (ECAD), lumen formation, and specific markers for lung 
epithelium (NKX2.1) and airway basal cells (P63) as assessed by immunostaining analyses 
(Fig. 9b)108,109. Taken together, these results demonstrate that this fully synthetic hydrogel 
supports the generation of ESC- and iPSC-derived HIOs from the intestinal spheroid stage 
without the use of MatrigelTM, and has the potential to be adapted for the generation of 
different human organoids.  
 36 
 
Figure 8: Gene expression levels of PEG-4MAL-encapsulated spheroids are comparable 
to those embedded in MatrigelTM. RNA levels of pluripotency (OCT4), endoderm 
(FOXA2), and epithelial junction (ZO1, ECAD and CLDN2) genes, as quantified by RT-
qPCR (mean ± SEM; n = 6 samples per condition). Unpaired two-tailed t-test was used to 
identify statistical differences between matrix types (**P < 0.01; ns, not significant). One 
experiment was performed. Primer sequences are provided in Supplementary Table 1. 
Primer sequences for RT-qPCR   
Human gene Forward primer Reverse primer 
4-Oct gtggaggaagctgacaacaa ggttctcgatactggttcgc 
FOXA2 cgactggagcagctactatgc tacgtgttcatgccgttcat 
CDX2 gggctctctgagaggcaggt ggtgacggtggggtttagca 
ECAD ttgacgccgagagctacac gaccggtgcaatcttcaaa 
CLDN2 aaggctctgcaaagaactgc ctgccaggctgacttctctc 
ZO1 gggaacaacatagagtgacgc ccccactctgaaaatgagga 




Figure 9: PEG-4MAL hydrogel supports HLO development comparable to 
MatrigelTM. (a) Transmitted light and fluorescence microscopy images of HIOs cultured 
in 4.0% PEG-4MAL-RGD hydrogels or MatrigelTM. HIO viability was assessed at 7 d after 
encapsulation. Bar, 500 μm. (b) Fluorescence microscopy images of HLO at 7 d after 
encapsulation in 4.0% PEG-4MAL-RGD hydrogel or MatrigelTM and labeled for e-
cadherin (ECAD), lung epithelia (NKX2.1), and basal cells (P63). DAPI, counterstain. “L” 
indicates HLO lumen. Bars, 25 μm. One experiment was performed with 6 PEG-
4MAL/MatrigelTM per condition (a,b). 
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3.3.4 Hydrogel-generated HIOs differentiate in vivo 
We next examined the potential of hydrogel-grown HIOs to differentiate into 
mature intestinal tissue in vivo as previously demonstrated104,110. mCherry-expressing 
spheroids that were embedded and grown within engineered PEG-4MAL hydrogels or in 
MatrigelTM for 3 weeks were recovered from their respective matrix and implanted under 
the kidney capsule of immunocompromised NSG mice (Fig. 10). In addition, HIOs grown 
in MatrigelTM for 2 weeks and then transferred and cultured within PEG-4MAL hydrogels 
for 1 week (Hydrogel-maintained) were implanted under the kidney capsule (Fig. 10a,b,d). 
After 12 weeks, implanted kidneys contained mCherry-expressing HIOs that were 10- to 
40-fold larger in area than at the time of implantation (Fig. 10a,b), consistent with previous 
reports. Dissected PEG-4MAL-generated HIOs showed differentiated intestinal epithelium 
that resembled mature human intestine with crypt-villus architecture and underlying lamina 
propria, muscularis mucosae and submucosa104, with structured collagen fibers (trichrome) 
and presence of differentiated goblet cells (alcian blue), comparable to MatrigelTM-
generated and Hydrogel-maintained organoids (Fig. 10c,d). Polarized epithelial 
differentiation of PEG-4MAL hydrogel-generated HIOs was demonstrated by 
immunostaining for β-CATENIN, EZRIN, ZO-1 and ECAD (Fig. 11a). Additionally, 
PEG-4MAL-generated organoid epithelium showed localized cell proliferation (KI67) at 
the base of the crypt where the intestinal stem cells reside, and expressed characteristic 
markers for the intestinal epithelial protein CDX2, enteroendocrine cells (CHGA), goblet 
cells (MUC2), and tuft cells (DCLK1)111. Furthermore, PEG-4MAL-generated HIOs 
expressed PDX1, demonstrating a duodenum regional identity (Fig. 11a)98. Expression was 
comparable to MatrigelTM-generated organoids and Hydrogel-maintained organoids (Fig. 
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11b). These results demonstrate that HIOs generated in the engineered synthetic matrix can 
differentiate into mature intestinal tissue in an in vivo environment to the same extent as 
HIOs generated within MatrigelTM. These findings establish engineered synthetic PEG-
4MAL hydrogels as a robust alternative to MatrigelTM with significant implications for 
translational medicine. 
 
Figure 10: PEG-4MAL-generated HIOs develop a mature intestinal tissue structure 
in vivo. (a) Micrographs of dissected kidneys containing HIOs generated within PEG-
4MAL-RGD, MatrigelTM, or generated within MatrigelTM and maintained within PEG-
4MAL-RGD. (b) Transmitted light and fluorescence microscopy (mCherry) images of 
harvested organoids. Bar, 0.5 cm. (c,d) H&E staining demonstrates mature human 
intestinal crypt-villus structure, and Alcian blue and trichrome staining reveal presence of 
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differentiated goblet cells and organized collagen fibers. Bar, 100 μm. One experiment was 
performed using 3 mice per experimental condition. 
 
Figure 11: PEG-4MAL-generated HIOs differentiate into mature intestinal tissue in 
vivo. (a,b) Fluorescence microscopy images of HIOs generated within (a) PEG-4MAL-
RGD, (b) MatrigelTM, or generated within MatrigelTM and maintained within PEG-4MAL-
RGD, and labeled for β-CATENIN, proliferative cells (KI67), epithelial apical polarity 
(EZRIN) and junctions (ZO-1 and ECAD), intestinal epithelial protein CDX2, 
enteroendocrine cells (CHGA), goblet cells (MUC2), tuft cells (DCLK1) and small 
intestinal marker (duodenum; PDX1). DAPI, counterstain. “L” indicates HIO lumen. 
White arrows show enteroendocrine cells or tuft cells. Bars, 50 μm. One experiment was 
performed using 3 mice per experimental condition. 
3.3.5 Hydrogels as a HIO delivery vehicle to heal colonic wounds 
A key advantage of the PEG-4MAL hydrogel system is control over gelling time 
so that the hydrogel components can be injected as a solution that gels in situ11. We 
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therefore explored the use of the engineered hydrogel as a delivery vehicle for HIOs into 
murine intestinal mucosal wounds using a murine colonoscope. HIOs generated in PEG-
4MAL hydrogels or MatrigelTM were recovered from their matrix, mixed with the hydrogel 
precursor solution, and injected at the site of mechanically-induced mucosal wounds in the 
distal colon of immunocompromised mice (Fig. 12a, Fig.136a)112. Wound closure was 
evaluated using a colonoscope, and fluorescence imaging showed localized expression of 
mCherry-positive tissue at the wound site 5 d post-injection (Fig. 12b). Immunostaining at 
4 weeks post-injection demonstrated that HIO delivery via the synthetic hydrogel resulted 
in HIO engraftment into host intestinal epithelial tissue as shown by positive staining for 
human nuclei (NUMA) to detect either HIOs generated in the PEG-4MAL hydrogel or 
MatrigelTM (Fig. 12c). Importantly, no staining was evident for no-injection control, only 
hydrogel, and HIOs injected in saline (Fig. 12c), demonstrating that the hydrogel delivery 
vehicle is required for HIO engraftment and wound repair. Examination of HIO 
engraftment at the wound edge demonstrated staining for human cells adjacent to host 
tissue which stained negative for human markers. Engraftment of human cells into the 
colonic wound was also confirmed by positive staining for human mitochondria (HUMIT; 
Fig. 13b). Furthermore, colonic wounds treated with HIOs delivered with hydrogel showed 
positive staining for an OLFM4 probe specific to human cells at the base of the crypt-like 
domain (Fig. 12d; Fig. 13c), a pattern consistent with staining in the normal adult human 
colon (Fig. 13c), which is also consistent with previous reports of human OLFM4 protein 
and/or mRNA localization113-115. Additionally, several negatively stained human crypt-like 
domains were adjacent to mouse intestinal crypts which stained positive for a mouse-
specific Lgr5 probe (Fig. 13d) via in situ hybridization116. These observations were 
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compared to control tissue sections from immunocompromised mice that did not undergo 
colonic injuries or received HIO injections (Fig. 12d; Fig. 13d).  
We also examined whether delivered HIOs promote colonic mucosal wound repair 
(Fig. 12e). Strikingly, delivery of HIOs to colonic wounds using the hydrogel carrier 
significantly increased wound closure compared to untreated wounds and wounds treated 
with hydrogel alone or HIOs without the carrier (Fig. 12e). No differences were observed 
in wound closure between HIOs generated in the synthetic hydrogels and MatrigelTM. 
Taken together, these results demonstrate that the engineered PEG-4MAL hydrogel serves 
as an injectable delivery vehicle that supports localized HIO engraftment in colonic 
mucosal wounds and enhances wound closure. These findings establish the clinical 
translational potential of the synthetic hydrogel as an in vivo delivery vehicle for hPSC-
derived HIOs and provide proof-of-concept that HIOs may be used therapeutically to treat 
intestinal injury or disease. 
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Figure 12: PEG-4MAL serves as an injectable delivery vehicle to promote HIO 
engraftment and wound closure. (a) PEG-4MAL-generated HIOs mixed with engineered 
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hydrogel precursor solutions were injected underneath mechanically-induced mucosal 
wounds, as seen through the colonoscope camera. (b) Mechanically-induced mucosal 
wound and fluorescence imaging (mCherry) at the wound site at 5 d post-injection. Bar, 
500 μm. (c) Fluorescence microscopy images of murine colonic tissue at the wound site 
labeled for human cell nuclei (NUMA) at 4 weeks post-delivery. Left: Images from wound 
edge showing insets from i) adjacent host tissue and ii) wound. Right: Images from wound 
center showing insets at wound site. DAPI, counterstain. Bars, 100 μm. (d) In situ 
hybridization, stained for human OLFM4+ cells. Bar, 50 μm. (e) Images of mucosal 
wounds at 1 d (prior to injection) or 5 d post-injury in murine colon as seen through the 
colonoscope camera. Mucosal wound area at 5 d post-injury was normalized to day 1 (prior 
to injection) values (mean ± SEM). Five colonic wounds per mouse were analyzed and 
averaged (n = 4 mice per condition). One-way ANOVA with Tukey’s multiple 
comparisons test showed significant difference between Hydrogel-grown HIOs in hydrogel 
(●) or Matrigel-grown HIOs in hydrogel (■) and Saline injected HIOs (▲) Only hydrogel 
(♦) or No injection group (X) (**P < 0.01, ***P < 0.001, ****P < 0.0001). Bars, 500 μm. 
Two independent experiments were performed and data is presented for one of the 
experiments. Experiments performed with 4 mice per experimental group (five colonic 
wounds/injections per mouse; a-e). 
 45 
 
Figure 13: PEG-4MAL hydrogel serves as an injectable delivery vehicle in colonic 
mucosal wound model and promotes HIO engraftment. (a) Mechanically-induced 
submucosal wounds were performed in the distal colon of mice using a mechanical probe 
through a mouse colonoscope. One day post-wounding HIOs generated in engineered 4% 
PEG-4MAL-RGD hydrogels or MatrigelTM were recovered from the matrix, mixed with 
the engineered hydrogel precursor solutions, and injected underneath the submucosal 
wounds. A group with no injections, HIOs injected in saline, or injection of HIO-free 
hydrogel precursor solutions were used as control groups. Distal colon tissue harvest, 
immunostaining and imaging was performed 4 weeks post-wounding. (b) Fluorescent 
microscopy images labeled for human mitochondria (HUMIT) of murine colonic tissue at 
the wound site at 4 weeks post-injection or control tissue. DAPI, counterstain. “L” indicates 
HIO lumen. Bars, 100 μm. (c) In situ hybridization images of (c) control adult human colon 
or sections taken at the mouse colonic wound site stained for human OLFM4+ cells. (d) In 
situ hybridization images of tissue sections from mice colon that did not undergo colonic 
injuries or received HIO injections (control) and sections taken at the mouse colonic wound 
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site stained for mouse Lgr5+ intestinal stem cells. Bars, 50 μm. Two independent 
experiments were performed and data is presented for one of the experiments. Experiments 
performed with 4 mice per experimental group (five colonic wounds/injections per mouse; 
b-d). 
3.4 Discussion 
In this study, we engineered a completely synthetic hydrogel that supports in vitro 
generation of intestinal organoids from hPSC-derived spheroids without the need of 
MatrigelTM encapsulation. Both mechanical and biochemical properties of the synthetic 
ECM were important to intestinal organoid formation, and we identified an optimal 
formulation that supports intestinal spheroid survival, expansion and epithelial 
differentiation into HIOs and differentiation into mature intestinal tissue in vivo to similar 
levels as MatrigelTM. Additionally, we showed that this synthetic matrix supports the 
development of other human organoids such as HLOs. The requirement for specific 
mechanical and cell adhesive properties in the synthetic matrix is consistent with previous 
work showing that epithelial cell cyst growth, polarization, and lumen formation are 
restricted to a narrow range of ECM elasticity and that adhesive peptide type regulates 
apicobasal polarity and lumenogenesis during epithelial morphogenesis in 3D cultures9. 
Interestingly, the mechanical properties and protease degradation characteristics that 
supported hPSC-derived organoids in this study are different from those recently identified 
for murine Lrg5+ intestinal stem cell growth and organoid formation100, which involved 
more complex, mechanically dynamic properties, and suggest differences between these 
two organoid sources. This fully synthetic matrix addresses major limitations of MatrigelTM 
associated with lot-to-lot compositional and structural variability and its tumor-derived 
nature that severely restrict scale-up applications and clinical translation. 
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We also established the use of the engineered hydrogel as a delivery vehicle for 
HIOs to murine intestinal mucosal wounds using a murine colonoscope. Although other 
studies have focused on the delivery of murine intestinal organoids into the colonic lumen 
as a suspension24, we showed that absence of a delivery vehicle reduces HIO engraftment 
at the implantation site. Injection of hydrogel liquid precursors and HIOs to mucosal 
wounds resulted in an in situ polymerized hydrogel that supported localized organoid 
engraftment and enhanced wound repair. Therefore, this delivery strategy forms a basis for 
the development of HIO-based therapies to treat gastrointestinal diseases in humans 
involving intestinal epithelial wounds (e.g., IBD). Furthermore, the modular nature of this 
hydrogel platform allows for the adaptation to in vitro generation and in vivo delivery of 
other human PSC-derived organoids (e.g., lung) for regenerative medicine. 
3.5 Methods 
Immunofluorescence analysis 
For immunofluorescence labeling of frozen sections from colon, HIOs, kidney capsule 
implanted-HIOs or HLOs, these were fixed with 3.7% (w/v) paraformaldehyde at room 
temperature for 15 min, followed by 0.5 % (w/v) Triton X-100 for 5 min. Primary antibody 
incubation was performed overnight at a 1:100 dilution, unless stated otherwise. Secondary 
antibody incubation was performed for 1 h at a 1:2000 dilution. Detailed information on 
the antibodies used including their resources (company names, catalogue numbers) and 
dilutions are provided in the Reporting Summary.  
Differentiation of hPSCs into intestinal spheroids or HLOs 
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All work using human pluripotent stem cells was approved by the University of Michigan 
Human Pluripotent Stem Cell Oversight Committee (HPSCRO). Stem cell lines are 
routinely monitored for chromosomal karyotype, pluripotency (using a panel of antibody 
and RT-qPCR markers), and for the ability to undergo multi-lineage differentiation. For 
intestinal spheroid generation, mycoplasma-free human ES cells (H9, NIH registry #0062) 
and iPS cells (line 20.1, source as previously described98) were cultured on Matrigel™-
coated plates and differentiated into intestinal tissue as previously described98. Floating 
spheroids present in the cultures on day 4 and day 5 of mid/hindgut induction were 
harvested for use in subsequent experiments. In some experiments, hESCs expressing a 
constitutively active H2BmCherry fluorescent reporter were used. This line was generated 
by infecting hESCs with a lentivirus containing PGK-H2BmCherry, which was a gift from 
Mark Mercola (Addgene plasmid # 21217)117. For HLO generation, human ES cells 
(UM63-1, NIH registry #0277) were maintained, differentiated and expanded into HLOs 
as previously described109.  
Hydrogel formation and in vitro intestinal spheroid/HIO  
To prepare PEG hydrogels, PEG-4MAL macromer (MW 22,000 or 44,000; Laysan Bio) 
was dissolved in 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) buffer (20 
mM in DPBS, pH 7.4). Adhesive and GPQ-W crosslinking peptides were custom 
synthesized by AAPPTec. Adhesive peptides RGD (GRGDSPC), AG73 
(CGGRKRLQVQLSIRT), GFOGER (GYGGGP(GPP)5GFOGER (GPP)5GPC), IKVAV 
(CGGAASIKVAVSADR) and RDG (GRDGSPC) were dissolved in HEPES at 10.0 mM 
(5X final ligand density) and mixed with PEG-4MAL at a 2:1 PEG-4MAL/ligand ratio to 
generate functionalized PEG-4MAL precursor. Bis-cysteine crosslinking peptide GPQ-W 
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(GCRDGPQG↓IWGQDRCG; ↓ denotes enzymatic cleavage site) or non-degradable 
crosslinking agent DTT (1,4-dithiothreitol; 3483-12-3, Sigma) was dissolved in HEPES at 
a density corresponding to 1:1 maleimide/cysteine ratio after accounting for maleimide 
groups reacted with adhesive peptide. For HIOs encapsulation, spheroids were embedded 
and expanded in MatrigelTM for up to 30 d. Resulting HIOs were dislodged from the 
MatrigelTM and resuspended at 5X final density (final density: 2-4 HIOs/hydrogel) in 
intestine growth medium118 and kept on ice. For human intestinal spheroid encapsulation, 
spheroids were harvested immediately after differentiation and were resuspended at 5X 
final density (final density: 20-30 spheroids/hydrogel) in intestine growth medium and kept 
on ice. For HLOs encapsulation, these were dislodged from the MatrigelTM and 
resuspended at 5X final density (final density: 2-4 HLOs/hydrogel) in foregut growth 
medium107,108 and kept on ice. To form hydrogels, adhesive peptide-functionalized PEG-
4MAL macromer, cells, and crosslinking peptide were polymerized for 20 min before 
addition of intestine growth medium. MatrigelTM-generated hPSC-derived HIOs were 
generated and cultured as described previously98,118. Passaging of HIOs cultured in PEG-
4MAL hydrogels was performed similarly to tissue embedded in MatrigelTM, as previously 
described107,118. Briefly, HIOs were dislodged from the PEG-4MAL hydrogel, transferred 
to a sterile Petri dish, and manually cut into halves using a scalpel. HIO halves were 
resuspended at 5X final density (final density: 2-4 HIOs/hydrogel) in intestine growth 
medium118 and mixed with hydrogel precursor solutions to form PEG-4MAL hydrogels. 
HIOs were passaged up to 3 times over the course of 3 weeks. MatrigelTM-generated HIOs 
were passaged as described previously98,118. Sample size was established as at least 4 
hydrogels per condition with the premise that an outcome present in 4 different hydrogels 
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under a specific condition will reveal the population behavior submitted to this given 
condition. 
Hydrogel characterization 
The storage and loss moduli of hydrogels were assessed by dynamic oscillatory strain and 
frequency sweeps performed on a MCR 302 stress-controlled rheometer (Anton Paar) with 
a 9-mm diameter, 2° cone, and plate geometry. Oscillatory frequency sweeps were used to 
examine the storage and loss moduli (ω = 0.5–100 rad s-1) at a strain of 2.31%. 
Viability assay and quantification 
PEG-4MAL gels were incubated in 2 μM calcein-AM (live; Life Technologies), and 1 μM 
TOTO-3 iodide (dead; Life Technologies) in growth medium for 1 hr. Samples were 
imaged using an Axiovert 35, Zeiss microscope. Quantification of viability was performed 
by calculating the percentage of the total projected area of a spheroid/organoid that stained 
positive for the live or dead stain using ImageJ (National Institute of Health, USA). The 
results are representative of three different experiments performed with 6 PEG-
4MAL/MatrigelTM per condition 
Inhibition of mediators of mechanotransduction 
Inhibition of YAP, myosin II or Rho-associated kinase was performed using verteporfin 
(SML0534, Sigma), blebbistatin (203389, Calbiochem) and Y-27632 (688002, 
Calbiochem), respectively, by adding 10 or 30 µM to the intestine growth medium 20 min 
after spheroid encapsulation in hydrogel. Cell apoptosis/death was assessed 1 d after 
encapsulation using Annexin V/Dead Cell Apoptosis Kit (A13201, ThermoFisher). 
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Samples were imaged using an Axiovert 35, Zeiss microscope. The results are 
representative of two different experiments performed with 6 PEG-4MAL/MatrigelTM per 
condition. 
RT-qPCR 
Total RNA from hESC day 0 spheroids or HIOs grown in PEG-4MAL hydrogels or 
MatrigelTM was extracted using the MagMax RNA isolation system and MagMax-96 total 
RNA isolation Kit (AM1830, ThermoFisher Scientific). cDNA was synthesized using the 
SuperScript VILO cDNA Synthesis Kit (11754-250, ThermoFisher Scientific). RT-qPCR 
was carried out using the QuantiTect SYBR Green PCR Kit (204145, Qiagen). Relative 
gene expression was plotted as Arbitrary Units using the formula: [2^(housekeeping gene 
Ct – gene of interest Ct)] x 10,000.  Primer sequences for RT-qPCR are provided in 
Supplementary Table 2. 
Animal models  
All animal studies were conducted following approved protocols established by University 
of Michigan’s Institutional Animal Care and Use Committee (IACUC) in accordance with 
the U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service 
(APHIS) regulations and the National Institutes of Health (NIH) Office of Laboratory 
Animal Welfare (OLAW) regulations governing the use of vertebrate animals. Male (8 
weeks old) NOD-scid IL2Rg-null (NSG) mice (Jackson Laboratory) were used for all our 
experiments. Sample size was established as 3 with the premise that an outcome present in 
3 different animals under a specific condition will reveal the population behavior submitted 
to this given condition. No statistical method was used to predetermine sample size. 
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Kidney capsule implantation 
Organoids were implanted under the kidney capsule of male NOD-scid IL2Rg-null (NSG) 
mice (Jackson Laboratory) as previously described (Watson et al., 2014 and Finkbeiner et 
al., 2015)104.  Briefly, mice were anesthetized using 2% isofluorane. The left flank was 
shaved and sterilized using chlorhexidine and isopropyl alcohol. A left flank incision was 
used to expose the kidney. HIOs were manually placed in a subcapsular pocket of the 
kidney using forceps. An intraperitoneal flush of Zosyn (100 mg/kg; Pfizer) was 
administered prior to closure in two layers. The mice were sacrificed and transplant 
retrieved after 12 weeks. The results are representative of one experiment performed with 
3 mice per condition (one organoid implanted per kidney capsule). 
Colonic mucosal wound and HIO injections 
NSG mice were anesthetized by intraperitoneal injection of a ketamine (100 
mg/kg)/xylazine (10 mg/kg) solution. A high-resolution miniaturized colonoscope system 
equipped with biopsy forceps (Coloview Veterinary Endoscope, Karl Stortz) was used to 
biopsy-injure the colonic mucosa at 3–5 sites along the dorsal artery. Wound size averaged 
approximately 1 mm2. HIO injection was performed on day 1 after wounding with the aid 
of a custom-made device comprising a 27-gauge needle (OD: 0.41 mm) connected to a 
small tube (Fig. 13a). Endoscopic procedures were viewed with high-resolution (1,024 × 
768 pixels) live video on a flat-panel color monitor. The results are representative of two 
independent experiments performed with 4 mice per condition (five colonic 
wounds/injections per mouse). 
Wound closure quantification 
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Mice were anesthetized by intraperitoneal injection of a ketamine (10 g/l) xylazine (8 g/l) 
solution (10 μl/g body weight). To create mucosal injuries in the mouse colon and to 
monitor their regeneration, a high-resolution colonoscopy system was used. Each wound 
region was digitally photographed at day 1 and day 5, and wound areas were calculated 
using ImageJ (National Institute of Health, USA). In each experiment, 3 - 4 lesions per 
mouse were examined. 
In situ hybridization (ISH) 
ISH for mouse Lgr5 expression was performed on frozen sections fixed with 4% 
paraformaldehyde (PFA). Slides were permeabilized with proteinase K (3115887001, 
Sigma-Aldrich) for 30 min at 37°C, washed with Saline-Sodium Citrate buffer and then 
acetylated at room temperature for 10 min. Pre-hybridization step was performed for 1 h 
at 37°C in a humidified chamber. A DIG-labeled riboprobe diluted in hybridization buffer 
was incubated overnight at 68°C. The slides were then washed and blocked for 1 h at room 
temperature followed by incubation with DIG antibody (11093274910, Sigma-Aldrich) 
overnight at 4°C. The developer solution (11681451001, Roche) was incubated for 72 h 
until the Lgr5 cells became evident. ISH for OLFM4 was performed using the RNAscope 
2.5 HD manual assay with brown chromogenic detection (Advanced Cell Diagnostics, Inc.) 
per manufacturer’s instructions. The human 20 base pair OLFM4 probe was generated by 
Advanced Cell Diagnostics targeting 20 base pairs within 1111-2222 of OLFM4 (gene 
accession NM_006418.4) and is commercially available. The results are representative of 
two independent experiments performed with 4 mice per condition (five colonic 
wounds/injections per mouse). 
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Statistics 
All statistical analyses were performed using GraphPad Prism 6.0. Statistical significance 
was calculated by one-way analysis of variance (ANOVA) with Tukey’s multiple 
comparisons test, two-way repeated measures ANOVA, or unpaired t-test with Welch’s 
correction, as described in the figure legends. P-values of statistical significance are 
represented as ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. 
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CHAPTER 4. SYNTHETIC HYDROGELS RECAPITULATE 
EPITHELIAL TUBULAR MORPHOGENETIC PROGRAM 
4.1 Abstract 
Recapitulating cell-extracellular matrix (ECM) interactions that regulate epithelial 
morphogenesis in a 3D in vitro environment is important to understand the formation of 
rudimentary epithelial organs. Therefore, naturally-derived materials have been used in 
organotypic cultures to recreate different kidney-associated tubular morphogenetic 
developmental programs. However, the lot-to-lot variability and inability of these materials 
to uncouple biophysical and biochemical matrix properties limit their reliability and use 
for the understanding of the independent contributions of physicochemical matrix 
properties to epithelial morphogenesis. Therefore, we engineered a fully defined, synthetic 
PEG-4MAL hydrogel with independent control over proteolytic degradation, mechanical 
properties, and adhesive ligand type and density to study the impact of ECM properties on 
the epithelial tubulogenesis program. We showed that sensitivity of the synthetic material 
to membrane-type matrix metalloproteinase-1 (MT1-MMP) was required for epithelial 
tubulogenesis. Additionally, a narrow range of matrix elasticity, presentation of specific 
adhesive ligand type, and a threshold level of adhesive ligand density of the MT1-MMP-
sensitive hydrogel were important to direct epithelial tubulogenesis. Finally, we 
demonstrated that the engineered PEG-4MAL hydrogel supported organization of 
epithelial tubules that displayed lumen formation, polarization and secreted ECM 
components. The PEG-4MAL hydrogel serves as a platform to recapitulate epithelial 
tubular morphogenetic programs and to characterize the independent contributions of the 
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matrix properties to distinctive normal or abnormal epithelial phenotypes, while 
overcoming the limitations of natural materials. 
4.2 Introduction 
The extracellular matrix (ECM) provides mechanical and biochemical signals that 
convey important signals in modulating renal epithelium morphogenesis9,119. For instance, 
the ECM provides physical support for the three-dimensional (3D) spatial organization of 
renal epithelial cells into tubular structures. Additionally, interactions between ECM 
components and integrins receptors regulate mechanotransduction pathways and modulate 
the activity of signaling molecules (e.g. Wnt family) that mediate the formation of a 
polarized and differentiated epithelium119,120. In order to better understand these ECM 
contributions to epithelial tubulogenesis, 3D collagen gels and MatrigelTM have been used 
in organotypic in vitro cultures that recreate the epithelial morphogenetic developmental 
program121,122. In these naturally-derived matrices, murine inner medullary collecting duct 
(IMCD) cells proliferate from single cells to form multicellular tubular structures, 
recapitulating the morphogenetic program of a rudimentary epithelial organ123,124 (Fig. 
14a). Nevertheless, these natural matrices are inherently limited by lot-to-lot compositional 
and structural variability, and the inability to decouple biochemical and biomechanical 
properties8,18. Additionally, in the case of MatrigelTM, its tumor-derived nature limits its 
translational potential4,8. Recently, a synthetic material containing animal-derived 
components that support epithelial tubulogenesis programs have been reported as an 
alternative to natural matrices125. 
Here, we describe a synthetic hydrogel that supports the epithelial morphogenesis 
program of IMCD cells without the use of naturally-derived materials or naturally-based 
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hydrogels. IMCD cells within PEG-4MAL hydrogels exhibit different multicellular 
structure phenotypes that can be classified as either “smooth clusters”, “spiked clusters”’ 
which were clusters with extensions, or “tubules”, in accordance with previous 
reports125,126 (Fig. 14b-d). Protease sensitivity, matrix elasticity, and adhesive ligand type 
and density of the synthetic hydrogel were important parameters to be considered for the 
engineering of a fully-synthetic matrix that supported the IMCD cell tubulogenesis 
program. The modular, well-defined design of this synthetic matrix overcomes limitations 
associated with the use of naturally-derived materials. 
We selected a hydrogel platform based on a four-armed, maleimide-terminated 
poly(ethylene glycol) (PEG-4MAL) macromer that presents elements inspired by the ECM 
such as cell adhesion peptides and matrix metalloproteinase (MMP)-sensitive crosslinking 
peptides. Although other synthetic hydrogel systems have been developed to mimic 
properties of natural ECM, the PEG-4MAL hydrogel platform exhibits significant 
advantages including well-defined structure, stoichiometric incorporation of bioactive 
motifs, increased cytocompatibility, and improved crosslinking efficiency9,10,127. 
Additionally, the tunable properties of PEG-4MAL hydrogels allow the study of the 
independent contributions of the biophysical and biochemical matrix properties on both 
single and collective epithelial cell programs9,127. For instance, we showed using this 
platform that normal epithelial cyst growth, polarization, and lumen formation of Madin-
Darby Canine Kidney (MDCK) cells were restricted to a narrow range of matrix elasticity, 
required a threshold level of cell-directed matrix degradability, and were dramatically 
regulated by adhesive peptide density9. Therefore, the modular design of this synthetic 
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matrix allows the study of the independent contributions of physicochemical matrix 
properties to IMCD cell tubulogenesis. 
 
Figure 14: Epithelial IMCD cells proliferate to form multicellular tubular structures. (a) 
IMCD cells within type I collagen gels proliferate to form multicellular tubular structures 
over time. (b-d) IMCD cells within PEG-4MAL hydrogels exhibit different multicellular 
structure phenotypes. Transmitted light microscopy images of IMCD multicellular 
structures within PEG-4MAL hydrogels forming (b) smooth cluster, (c) spiked clusters, or 
(d) tubules after 21 d post-encapsulation. Blue arrows indicate (c) spikes or (d) tubules in 
multicellular IMCD structures. Bars, 100 μm. 
4.3 Results 
4.3.1 PEG-4MAL hydrogel supports MT1-MMP-directed tubule formation in a polymer 
density-dependent manner 
PEG-4MAL hydrogels were functionalized with adhesive peptides and crosslinked 
in the presence of IMCD cells to generate PEG-4MAL hydrogels (Fig. 15a,b). The 
mechanical properties of the hydrogel were tuned by varying polymer density (Fig. 15c). 
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Because ECM mechanical properties influence epithelial cell behaviors9,127, we 
investigated the influence of hydrogel polymer density (5-7% wt/vol; 10 kDa PEG-4MAL 
macromer size) on IMCD cell viability, proliferation and tubule formation (Fig. 16). This 
combination of macromer size and polymer densities can produce hydrogels with 
mechanical properties (storage modulus, G’: 500 Pa) that has been demonstrated to support 
epithelial tubulogenesis125. Moreover, these synthetic hydrogels were engineered to present 
a constant 2.0 mM RGD adhesive peptide (GRGDSPC) density and crosslinked with the 
collagen-derived, protease-degradable peptide GPQ-W (GCRDGPQGIWGQDRCG). 
These adhesive peptide type and density and crosslinking peptide have been shown to 
support epithelial cell viability and cyst morphogenesis in PEG-4MAL hydrogels9,127. 
After 14 d in culture, IMCD cells showed high viability in all hydrogel conditions (Fig. 
16a) and a polymer density-dependent effect on projected area and longest distance 
between two points along the projected area (Feret diameter; Fig. 16b,c). At 21 d post-
encapsulation, no tubule formation or cell spreading was shown (Fig. 16d), and size 
analysis demonstrated a polymer density-dependent effect on projected area Feret diameter 
of the IMCD cell structures (Fig. 16e,f). Nevertheless, no significant differences in 
projected area or Feret diameter of encapsulated cellular clusters were observed between 
day 14 and 21 (Fig. 16g,h), demonstrating that the examined PEG-4MAL hydrogel 
properties do not support IMCD cell structure growth and tubulogenesis.  
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Figure 15: PEG-4MAL hydrogel preparation and mechanical properties. (a) PEG-
4MAL macromers are conjugated with thiol-containing adhesive peptide to produce a 
functionalized PEG-4MAL macromer, which is then crosslinked in the presence of cells 
using protease-cleavable peptides containing terminal cysteines to form (b) a hydrogel 
network. (c) Relationship between polymer density (wt%) and storage modulus (mean ± 
SEM) of 10 kDa PEG-4MAL hydrogels functionalized with 2 mM RGD and crosslinked 
with GPQ-W or IPES. (d) Relationship between polymer density (wt%) and storage 
modulus (mean ± SEM) of 20 kDa PEG-4MAL hydrogels functionalized with 2 mM (for 
6, 8, 10, 12 and 14%) or 4 mM RGD (for 9.15%) and crosslinked with IPES. Each data 
point represents an independently prepared hydrogel. Analysis performed to at least 4 PEG-
4MAL hydrogels per experimental group. 
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Figure 16: PEG-4MAL hydrogel crosslinked with GPQ-W peptide does not support 
tubule formation. (a) Transmitted light and fluorescence microscopy images of IMCD 
cells cultured in PEG-4MAL hydrogels of different polymer density and crosslinked with 
GPQ-W peptide. IMCD cell viability was assessed at 14 d after encapsulation. Bar, 100 
μm. IMCD multicellular structure (b) projected area and (c) Feret diameter at 14 d after 
encapsulation in PEG-4MAL hydrogel. (d) Transmitted light images of IMCD cells at 21 
d after encapsulation in PEG-4MAL hydrogel. Bar, 500 μm. IMCD multicellular structure 
(e) projected area and (f) Feret diameter at 21 d after encapsulation in PEG-4MAL 
hydrogels. Comparison of IMCD multicellular structure (g) projected area and (h) Feret 
diameter at 14 d and 21 d after encapsulation in PEG-4MAL hydrogels. Graph lines 
represents the mean of the individual data points. Each data point represents one 
multicellular structure. Krustal-Wallis with Dunn’s multiple comparisons test or unpaired 
t-test with Welch’s correction was used. P-values of statistical significance are represented 
as ****P < 0.0001, ***P < 0.0002, **P < 0.0021, *P < 0.0332. A p-value < 0. 0332 was 
considered significant. Experiments performed with 6 PEG-4MAL hydrogels per 
experimental group. 
Considering that proteolytic cleavage of ECM components by MT1-MMPs is 
essential for renal cell proliferation and tubulogenesis119,128, we then examined whether 
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crosslinking of PEG-4MAL hydrogels with an MT1-MMP-sensitive crosslinking peptide 
is necessary to support IMCD cell tubulogenesis. These type of membrane-bound MMPs 
have been demonstrated to have an important role in directing renal development by cell-
directed matrix remodeling and supporting IMCD cell proliferation and migration128. For 
this purpose, IMCD cells were encapsulated in RGD-functionalized hydrogels of different 
polymer densities (5 – 8%, 10kDa PEG-4MAL) and crosslinked with the MT1-MMP-
sensitive crosslinking peptide IPES (GCRDIPESLRAGDRCG)129,130. These IPES-
crosslinked hydrogels exhibited mechanical properties comparable to hydrogels of equal 
polymer densities but crosslinked with GPQ-W peptide (Fig. 15c). IMCD cells embedded 
in PEG-4MAL hydrogels maintained high viability 1 d post-encapsulation in all conditions 
(Fig. 17a,b). After 5 d in culture, IMCD cells had generated cellular clusters that showed a 
significant polymer density-dependent effect on cell proliferation, projected area and Feret 
diameter (Fig. 17c-f). When IMCD cell culture continued for at least 21 d, some of the cell 
clusters within the 5% and 6% hydrogels developed tubules, as opposed to cells within 7% 
and 8% hydrogels which remained as cellular clusters (Fig. 17g). These results suggest that 
GPQ-W crosslinking peptide does not support IMCD tubulogenesis due to its relatively 
low enzymatic specificity to MT1-MMPs129,130, and that polymer density has a direct effect 
on IMCD cell proliferation, multi-cellular growth and tubule formation. Although 5% 
PEG-4MAL hydrogels supported tubule formation, this formulation was less mechanically 
stable compared with 6% PEG-4MAL hydrogels by 21 d in culture. We therefore selected 
6.0% (10kDa) PEG-MAL hydrogels crosslinked with the MT1-MMP-sensitive IPES 




Figure 17: Polymer density of 10 kDa PEG-4MAL directs tubule formation. (a) 
Percentage of IMCD cells that stained for live (mean ± SEM) after 1 d of encapsulation in 
10 kDa PEG-4MAL hydrogels of different polymer density. Each data point represents one 
independent hydrogel. At least 100 cells were assessed per condition. (b) Fluorescence 
microscopy images of IMCD cells cultured in PEG-4MAL hydrogels of different polymer 
density. IMCD cell viability was assessed at 1 d after encapsulation. Bar, 100 μm. (c) 
Percentage of IMCD cells per cluster that were labeled by EdU incorporation (mean ± 
SEM) after 5 d of encapsulation. At least 30 clusters were analyzed per condition. (d) 
Transmitted light and fluorescence microscopy images of proliferating (EdU) IMCD cells 
cultured in PEG-4MAL hydrogels of different polymer density. IMCD cell proliferation 
was assessed at 5 d after encapsulation. Bar, 50 μm. IMCD multicellular structure (e) 
projected area and (f) Feret diameter at 5 d after encapsulation in PEG-4MAL hydrogel. 
Graph line represents the mean of the individual data points. Each data point represents 
one multicellular structure. (g) Transmitted light and fluorescence microscopy images of 
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IMCD cells at 21 d after encapsulation in PEG-4MAL hydrogel and labeled for actin 
(phalloidin). DAPI, counterstain. Bars, 100 μm. Krustal-Wallis with Dunn’s multiple 
comparisons test was used. P-values of statistical significance are represented as ****P < 
0.0001, ***P < 0.0002, **P < 0.0021, *P < 0.0332. A p-value < 0. 0332 was considered 
significant. All experiments performed with at least 6 PEG-4MAL hydrogels per 
experimental group. Experiments performed with 6 PEG-4MAL hydrogels per 
experimental group. 
4.3.2 Adhesive peptide type directs tubule formation 
Interactions between adhesion receptors and ECM components provide signals 
critical for cell survival, proliferation and differentiation4,101. Therefore, we examined 
whether the adhesive ligand type in the synthetic hydrogel impacts tubule formation. IMCD 
cells were embedded within 6% PEG-4MAL (10kDa) hydrogel formulations crosslinked 
with a constant IPES density but functionalized with different cysteine-terminated adhesive 
peptides (all at 2.0 mM; Fig. 18): RGD, inactive scrambled peptide RDG (GRDGSPC), 
type I collagen-mimetic triple helical GFOGER 
(GYGGGP(GPP)5GFOGER(GPP)5GPC)
103, and laminin β1 chain-derived YIGSR 
(CGGEGYGEGYIGSR)30. IMCD cells encapsulated in RGD-functionalized hydrogels 
maintained the highest level of proliferation (Fig. 18a,b) and showed significant increase 
in projected area and Feret diameter as compared to GFOGER- or YIGSR-functionalized 
hydrogels at 5 d post-encapsulation (Fig. 18c,d). Additionally, IMCD cells encapsulated in 
PEG-4MAL hydrogels functionalized with inactive RDG peptide showed significant 
reduction in cell proliferation when compared to RGD (Fig. 18a,b) and reduced growth 
over all hydrogel conditions (Fig. 18c,d). Furthermore, at 21 d post-encapsulation cell 
structures were classified as either “smooth clusters”, “spiked clusters”’ which were 
clusters with extensions, or “tubules”, in accordance with previous reports125,126 (Fig. 18e; 
Fig. 14). IMCD cell tubule formation was observed in the RGD and GFOGER conditions, 
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whereas cells encapsulated in RDG or YIGSR-functionalized hydrogels did not generated 
tubules (Fig. 18e,f). These results suggest an adhesive peptide type-dependent effect on 
tubule morphogenesis of IMCD cells after 21 d in culture. As RGD-functionalized 
hydrogels supported the highest level of cell proliferation, and significant growth than 
GFOGER, we used RGD-functionalized hydrogels for subsequent studies.  
 
Figure 18: Adhesive peptide type in PEG-4MAL hydrogels directs tubule formation. 
(a) Percentage of IMCD cells per cluster that were labeled by EdU incorporation (mean ± 
SEM) after 5 d of encapsulation in PEG-4MAL hydrogels functionalized with different 
adhesive peptides. At least 30 clusters were analyzed per condition. (b) Transmitted light 
and fluorescence microscopy images of proliferating (EdU) IMCD cells cultured in PEG-
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4MAL hydrogels functionalized with different adhesive peptides. IMCD cell proliferation 
was assessed at 5 d after encapsulation. Bar, 50 μm. IMCD multicellular structure (c) 
projected area and (d) Feret diameter at 5 d after encapsulation in PEG-4MAL hydrogel. 
Graph line represents the mean of the individual data points. Each data point represents 
one multicellular structure. (e) Percentage of IMCD multicellular structures (mean ± SEM) 
that classified as either “smooth clusters”, “spiked clusters”, or “tubules” after 21 d of 
encapsulation. At least 10 multicellular structures were analyzed per condition. (f) 
Fluorescence microscopy images of IMCD cells at 21 d after encapsulation in PEG-4MAL 
hydrogel and labeled for actin (phalloidin). DAPI, counterstain. Bars, 50 μm. (a,c,d) 
Krustal-Wallis with Dunn’s multiple comparisons test was used. (e) χ2 test with 
Bonferroni’s correction was used; *, P < 0.0002 for RGD vs RDG and P < 0.0021 for RGD 
vs YIGSR. P-values of statistical significance are represented as ****P < 0.0001, ***P < 
0.0002, **P < 0.0021, *P < 0.0332. A p-value < 0. 0332 was considered significant. 
Experiments performed with 6 PEG-4MAL hydrogels per experimental group. 
4.3.3 PEG-4MAL macromer size promotes early tubulogenesis 
As previous studies have demonstrated that matrix elasticity influence epithelial 
cell behaviors9,127, we investigated the influence of PEG-4MAL macromer size (10 and 20 
kDa), which controls hydrogel mechanical properties9,127, on IMCD cell viability, 
proliferation and tubule formation. As changes in PEG-4MAL macromer size and polymer 
density modulates synthetic matrix elasticity, IMCD cells were encapsulated in PEG-
4MAL hydrogels of 20 kDa macromer size and a range of polymer densities (8-14% 
wt/vol) that exhibit a different range of matrix elasticity (Fig. 15d) as compared to 10 kDa 
PEG-4MAL hydrogels (Fig. 15c). We chose 20 kDa PEG-4MAL hydrogel as this 
macromer size have been previously used to recapitulate epithelial morphogenetic 
programs9,127. The synthetic hydrogels were functionalized with the adhesive ligand RGD 
and crosslinked using the MT1-MMP-sensitive IPES sequence. No differences in cell 
viability were observed in any of the hydrogel conditions at 1 d post-encapsulation (Fig. 
19a,b), whereas IMCD cell proliferation, projected area and Feret diameter varied in a 
polymer density-dependent manner at 5 d post-encapsulation (Fig. 19c-f). Moreover, as 
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early as 7 d after encapsulation cell spreading was observed in the 8% condition whereas 
cell clusters continued to develop in all other conditions (Fig. 19g). By 14 d of culture in 
the synthetic matrix, tubule formation was observed in a polymer density-dependent 
manner, where the 8% PEG-4MAL condition had a higher number of cell structures 
presenting tubules whilst significantly less tubule formation was observed in the higher 
(12% and 14%) polymer density conditions (Fig. 20a,b). Further analysis of the Feret 
diameter of tubule-presenting cell structures demonstrated a significantly higher length of 
tubules in the 8% 20 kDa PEG-4MAL hydrogels, as compared to tubules formed in 6%, 
10 kDa hydrogels (Fig. 20c). Therefore, these results demonstrate that IMCD cell 
encapsulation in PEG-4MAL hydrogels of 20 kDa macromer size resulted in cell spreading 
and tubule formation at an earlier time point and with an increased length of tubules, when 
compared to IMCD tubules formed in synthetic hydrogels of 10 kDa macromer size (Figs. 
16, 19 and 20). Finally, additional observations demonstrated that, by 7 d post-
encapsulation, cell viability was compromised in softer (6%, 20 kDa; Fig. 14d and Fig. 
21a) or in GPQ-W-crosslinked (8%, 20 kDa; Fig. 21b) PEG-4MAL hydrogels, as compared 
to 8%, 20 kDa PEG-4MAL hydrogels (Fig. 21c). Therefore, we designated 8%, 20 kDa as 
the optimized polymer density and macromer size that provides the physical support and 
biomechanical signals necessary for optimal IMCD cell growth and tubule formation 
within PEG-4MAL hydrogels.  
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Figure 19: Polymer density of 20 kDa PEG-4MAL directs tubule formation. (a) 
Percentage of IMCD cells that stained for live (mean ± SEM) after 1 d of encapsulation in 
20 kDa PEG-4MAL hydrogels of different polymer density. Each data point represents one 
independent hydrogel. At least 100 cells were assessed per condition. (b) Fluorescence 
microscopy images of IMCD cells cultured in PEG-4MAL hydrogels of different polymer 
density. IMCD cell viability was assessed at 1 d after encapsulation. Bar, 50 μm. (c) 
Percentage of IMCD cells per cluster that were labeled by EdU incorporation (mean ± 
SEM) after 5 d of encapsulation. At least 30 clusters were analyzed per condition. (d) 
Fluorescence microscopy images of proliferating (EdU) IMCD cells cultured in PEG-
4MAL hydrogels of different polymer density. IMCD cell proliferation was assessed at 5 
d after encapsulation. Bar, 50 μm. IMCD multicellular structure (e) projected area and (f) 
Feret diameter at 5 d after encapsulation in PEG-4MAL hydrogel. Graph line represents 
the mean of the individual data points. Each data point represents one multicellular 
structure. (g) Transmitted light and fluorescence microscopy images of IMCD cells at 7 d 
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after encapsulation in PEG-4MAL hydrogel. Bars, 100 μm for 8% and 200 μm for other 
conditions. Krustal-Wallis with Dunn’s multiple comparisons test was used. P-values of 
statistical significance are represented as ****P < 0.0001, ***P < 0.0002, **P < 0.0021, 
*P < 0.0332. A p-value < 0. 0332 was considered significant. Experiments performed with 
6 PEG-4MAL hydrogels per experimental group. 
 
 
Figure 20: Polymer density and macromer size controls tubule formation. (a) 
Transmitted light images of IMCD cells cultured in 20 kDa PEG-4MAL hydrogels of 
different polymer density at 14 d after encapsulation. Bar, 200 μm. (b) Percentage of IMCD 
multicellular structures (mean ± SEM) that classified as either “smooth clusters”, “spiked 
clusters”, or “tubules” after 21 d of encapsulation. At least 10 multicellular structures were 
analyzed per condition. χ2 test with Bonferroni’s correction was used; *, P < 0.0001 for 8% 
vs 12% and P < 0.0002 for 8% vs 14%. (c) IMCD multicellular structure Feret diameter at 
14 d after encapsulation in PEG-4MAL hydrogels of different macromere size. Graph line 
represents the mean of the individual data points. Each data point represents one 
multicellular structure. Unpaired t-test with Welch’s correction was used. P-values of 
statistical significance are represented as ****P < 0.0001, ***P < 0.0002, **P < 0.0021, 
*P < 0.0332. A p-value < 0. 0332 was considered significant. Experiments performed with 




Figure 21: Threshold level of PEG-4MAL mechanical properties and matrix degradability 
dictates IMCD cell viability. Transmitted light and fluorescence microscopy images of 
IMCD cells cultured in PEG-4MAL hydrogels of different conditions stained for dead. 
IMCD cell viability was assessed at 7 d after encapsulation on (a) 6%, 20 kDa PEG-4MAL-
RGD hydrogels crosslinked with IPES peptide, or (b) 8%, 20 kDa PEG-4MAL-RGD 
hydrogels crosslinked with GPQ-W peptide, or (c) 8%, 20 kDa PEG-4MAL-RGD 
hydrogels crosslinked with IPES peptide. Bar, 200 μm. Experiments performed with 6 
PEG-4MAL hydrogels per experimental group. 
4.3.4 Adhesive ligand density in PEG-4MAL hydrogels regulates tubule formation 
We next examined the effects of RGD adhesive ligand density on tubulogenesis 
within PEG-4MAL hydrogels engineered to present optimized biophysical properties (8%, 
20 kDa PEG-4MAL). A total density (2.0 mM) of a mixture of cell-adhesive RGD peptide 
and scrambled inactive RDG peptide was used to vary RGD density (0.4–2.0 mM) while 
maintaining identical structures among hydrogel formulations and constant IPES 
crosslinking peptide density (Fig. 22). Additionally, a hydrogel condition with a total RGD 
density of 4.0 mM (9.15%, 20 kDa) was used while preserving equal IPES crosslinking 
peptide density and mechanical properties (Fig. 14d, Fig. 22). Cell viability and 
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proliferation at 1 and 5 d post-encapsulation, respectively, was insensitive to RGD peptide 
density (Fig. 22a-d). However, cluster area and Feret diameter showed a significant 
dependence on RGD density after 5 d of encapsulation (Fig. 22e,f). Hydrogels presenting 
low (<2.0 mM) RGD densities supported the formation of relatively small multicellular 
structures with no significant differences among the groups (0.4, 1.0 and 1.6 mM RGD; 
Fig. 22e,f). In contrast, hydrogels presenting high (≥2.0 mM) RGD density formed 
relatively large structures with no statistical differences between these groups (2.0 and 4.0 
mM RGD; Fig. 22e,f). Further analysis of cellular structures at 14 d post-encapsulation 
demonstrated an RGD density-dependent effect on the number of tubule-presenting cell 
structures and length of tubules (Fig. 22g-i). No significant differences were observed 
between the high-density (2 and 4 mM) RGD hydrogels. These results are consistent with 
previous studies that have shown that adhesive ligand density regulates epithelial 
morphogenesis independent of cell proliferation9, and suggest that high RGD density 
promotes increased integrin-mediated cell migration that allows formation of longer 
tubules within the synthetic hydrogels. Moreover, combination of adhesive peptides RGD 
and GFOGER in PEG-4MAL hydrogels did not improved IMCD cell viability (Fig. 23a,b), 
proliferation (Fig. 23c,d), growth (Fig. 23e,f), or tubule formation (Fig. 23g) compared to 
hydrogels functionalized with 2.0 mM RGD, suggesting that tubule development is 
dominated by integrin interactions with RGD peptide. Additionally, these results show that 
although high RGD peptide density is not required for initial viability, proliferation and 
generation of cell aggregates, robust formation and growth of tubules requires a high 
density of RGD in the matrix.  Taken together, these results identify an engineered 
hydrogel formulation (Storage modulus, G’: 200 Pa; 8% polymer density; 20 kDa 
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macromer size; 2.0 mM RGD adhesive peptide; IPES crosslinking peptide) that supports 
IMCD viability and optimized cell proliferation, growth and formation of tubules, and 
which was used for subsequent experiments. 
 
Figure 22: Adhesive ligand density in PEG-4MAL hydrogels regulates tubule 
formation. (a) Percentage of IMCD cells that stained for live (mean ± SEM) after 1 d of 
encapsulation in 8%, 20 kDa PEG-4MAL hydrogels functionalized with varying RGD 
density and crosslinked with IPES peptide. Each data point represents one independent 
hydrogel. At least 100 cells were assessed per condition. (b) Fluorescence microscopy 
images of IMCD cells cultured in PEG-4MAL hydrogel. IMCD cell viability was assessed 
at 1 d after encapsulation. Bar, 50 μm. (c) Percentage of IMCD cells per cluster that were 
labeled by EdU incorporation (mean ± SEM) after 5 d of encapsulation. At least 30 clusters 
were analyzed per condition. (d) Fluorescence microscopy images of proliferating (EdU) 
IMCD cells cultured in PEG-4MAL hydrogels of different polymer density. IMCD cell 
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proliferation was assessed at 5 d after encapsulation. Bar, 50 μm. IMCD multicellular 
structure (e) projected area and (f) Feret diameter at 5 d after encapsulation in PEG-4MAL 
hydrogel. Graph line represents the mean of the individual data points. Each data point 
represents one multicellular structure. (g) Transmitted light and fluorescence microscopy 
images of IMCD cells at 14 d after encapsulation in PEG-4MAL hydrogel. Bars, 100 μm. 
(h) Percentage of IMCD multicellular structures (mean ± SEM) that classified as “smooth 
clusters”, “spiked clusters”, or “tubules” after 14 d of encapsulation. At least 10 
multicellular structures were analyzed per condition. χ2 test with Bonferroni’s correction 
was used; *, P < 0.0021 for 2.0 vs 0.4 mM RGD. (i) IMCD multicellular structure Feret 
diameter at 14 d after encapsulation in PEG-4MAL hydrogel. Graph line represents the 
mean of the individual data points. Each data point represents one multicellular structure. 
Krustal-Wallis with Dunn’s multiple comparisons test was used. P-values of statistical 
significance are represented as ****P < 0.0001, ***P < 0.0002, **P < 0.0021, *P < 0.0332. 
A p-value < 0. 0332 was considered significant. Experiments performed with 6 PEG-
4MAL hydrogels per experimental group. 
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Figure 23: PEG-4MAL hydrogels regulates tubule formation via cell receptor interactions 
with RGD peptide. (a) Percentage of IMCD cells that stained for live (mean ± SEM) after 
1 d of encapsulation in 8%, 20 kDa PEG-4MAL hydrogels functionalized with RGD or 
GFOGER and RGD, and crosslinked with IPES peptide. Each data point represents one 
independent hydrogel. At least 100 cells were assessed per condition. (b) Fluorescence 
microscopy images of IMCD cells cultured in PEG-4MAL hydrogel. IMCD cell viability 
was assessed at 1 d after encapsulation. Bar, 50 μm. (c) Percentage of IMCD cells per 
cluster that were labeled by EdU incorporation (mean ± SEM) after 5 d of encapsulation. 
At least 30 clusters were analyzed per condition. (d) Fluorescence microscopy images of 
proliferating (EdU) IMCD cells cultured in PEG-4MAL hydrogels functionalized with 
different adhesive type and density. IMCD cell proliferation was assessed at 5 d after 
encapsulation. Bar, 50 μm. IMCD multicellular structure (e) projected area and (f) Feret 
diameter at 5 d after encapsulation in PEG-4MAL hydrogel. Graph line represents the mean 
of the individual data points. Each data point represents one multicellular structure. (g) 
Percentage of IMCD multicellular structures (mean ± SEM) that classified as “smooth 
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clusters”, “spiked clusters”, or “tubules” after 21 d of encapsulation. At least 10 
multicellular structures were analyzed per condition. (c,e,f) Unpaired t-test with Welch’s 
correction was used. P-values of statistical significance are represented as ****P < 0.0001, 
***P < 0.0002, **P < 0.0021, *P < 0.0332. A p-value < 0. 0332 was considered significant. 
Experiments performed with 6 PEG-4MAL hydrogels per experimental group. 
4.3.5 Engineered hydrogel support IMCD cell tubulogenesis program 
IMCD cell tubulogenesis program is characterized by the 3D assembly of epithelial 
cell into tubules and formation of a polarized and differentiated epithelium119. Interactions 
between laminin and integrin receptors are required for renal epithelial 
differentiation119,120,124,131,132. Therefore, to further characterize IMCD tubule 
differentiation we examined epithelial polarity and laminin secretion of IMCD cell tubules 
generated within the engineered synthetic matrix. For at least 21 d, the engineered synthetic 
hydrogel allowed a significant increase in the number of multicellular structures forming 
tubules over time (Fig. 24a). The hydrogel-generated IMCD tubules demonstrated an 
organized tubular assembly, appropriate apical polarization of the luminal protein, cystic 
fibrosis transmembrane conductance regulator (CFTR)133, and secretion of laminin into the 
basal side of the tubular structures119,128 (Fig. 24b,c).  
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Figure 24: Engineered PEG-4MAL hydrogel promotes epithelial polarity and laminin 
secretion. (a) Percentage of IMCD multicellular structures (mean ± SEM) that classified 
as either “smooth clusters”, “spiked clusters”, or “tubules” after 7, 14 and 21 d of 
encapsulation in the engineered hydrogel. χ2 test with Bonferroni’s correction was used; *, 
P < 0.0001 for day 7 vs day 21. At least 10 multicellular structures were analyzed per 
condition. (b) Fluorescence microscopy images of IMCD tubules within engineered 
hydrogel stained for apical polarity marker (CFTR) and secreted laminin (LM). (d) 
Transmitted light and fluorescence microscopy images of IMCD tubules within engineered 
hydrogel stained for CFTR, LM, actin (phalloidin) and nuclei (DAPI). Bars, 100 μm. 
Experiments performed with 6 PEG-4MAL hydrogels per experimental group. 
Moreover, we evaluated the role of integrin receptors and mediators of 
mechanotransduction pathways on IMCD cell tubulogenesis program within the 
engineered hydrogel. Previous studies have demonstrated that IMCD cells morphogenesis 
program requires sequential cell adhesion to ECM, via laminin (e.g. α3β1) and collagen 
(α1β1 and α2β1) receptors, that promotes cell spreading, proliferation and migration to 
ultimately form multicellular tubular structures119,124,132.  Addition of blocking antibodies 
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against α1, α2, and β1 integrin subunits resulted in a significant reduction of tubule 
formation at 21 d post-encapsulation as compared to control group (DMSO; Fig. 25). 
Additionally, treatment with blebbistatin or Y-27632, which inhibit myosin II and Rho-
associated kinase105,106, respectively, resulted in significant reduction of tubule formation 
as observed 21 d post-encapsulation (Fig. 25), suggesting that cellular contractility are 
important in the initial stages of IMCD tubulogenesis program. Finally, we also incubated 
IMCD cells embedded in the engineered hydrogel in an anti-MT1-MMP inhibitor or the 
broad-range MMP inhibitor GM6001, and demonstrated that IMCD cell viability was 
compromised after MT1-MMP inhibition within 7 d of culture (Fig. 26a), and no tubule 
formation was observed at day 21 after MMP inhibition by GM6001 (Fig. 26b,c), 
compared with the vehicle-only (DMSO) control. Previous in vitro studies have 
demonstrated that MT1-MMP expression is essential for renal epithelial branching 
tubulogenesis as early as 3 d post-encapsulation134, and expression of MMP-2 and MMP-
9 mediate embryonic branching morphogenesis119, suggesting that the engineered hydrogel 
supports MMP-mediated epithelial tubulogenesis. Taken together, these results 
demonstrate that the engineered PEG-4MAL hydrogel robustly supports tubular 
differentiation of IMCD cells. Additionally, these results provide preliminary indication 
that IMCD tubulogenesis in the synthetic matrix is also directed by cell receptor 
interactions with secreted laminin, and cellular contractility and MMP expression at initial 
stages of tubule development. 
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Figure 25: Engineered PEG-4MAL hydrogel promotes epithelial tubule differentiation via 
integrin receptors and cellular contractility. (a) Percentage of IMCD multicellular 
structures (mean ± SEM) that classified as either “smooth clusters”, “spiked clusters”, or 
“tubules” after 21 d of encapsulation in the engineered hydrogel and in the presence of 
inhibitors of integrin subunits and cellular contractility. χ2 test with Bonferroni’s correction 
was used; *, P < 0.0002 for DMSO vs α1, P < 0.0002 for DMSO vs α2, P < 0.0001 for 
DMSO vs β1, P < 0.0002 for DMSO vs blebbistatin, and P < 0.0012 for DMSO vs Y-27632. 
At least 10 multicellular structures were analyzed per condition. (b) Transmitted light 
images of IMCD multicellular structures at 21 d post encapsulation in the engineered 
hydrogel in the presence of inhibitors of integrin subunits and cellular contractility. Bars, 
200 μm. Experiments performed with 6 PEG-4MAL hydrogels per experimental group. A 
p-value < 0. 0332 was considered significant. 
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Figure 26: PEG-4MAL hydrogels supports MMP-mediated tubulogenesis. (a) 
Transmitted light and fluorescence microscopy images of IMCD cells cultured within 
engineered PEG-4MAL hydrogel and in the presence of an MT1-MMP inhibitor or vehicle 
control (DMSO). IMCD cell viability was assessed at 7 d after encapsulation. Bar, 100 μm. 
(b) Transmitted light and fluorescence microscopy images of IMCD cells cultured in 
engineered PEG-4MAL hydrogel and in the presence of a broad-range MMP inhibitor 
(GM6001) or vehicle control (DMSO). Bar, 100 μm. (c) Percentage of IMCD multicellular 
structures (mean ± SEM) that classified as “smooth clusters”, “spiked clusters”, or 
“tubules” after 21 d of encapsulation. At least 10 multicellular structures were analyzed 
per condition. χ2 test with Bonferroni’s correction was used; *, P < 0.0002 for DMSO vs 
GM6001. P-values of statistical significance are represented as ****P < 0.0001, ***P < 
0.0002, **P < 0.0021, *P < 0.0332. A p-value < 0. 0332 was considered significant. 
Experiments performed with 6 PEG-4MAL hydrogels per experimental group 
4.4 Discussion 
This study establishes a modular, fully synthetic hydrogel platform with controlled 
presentation of cell-adhesive ligands, tunable mechanical properties, and protease-
dependent degradation that can be precisely engineered to study the contributions of the 
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biophysical and biochemical matrix properties on the epithelial tubular morphogenetic 
program of murine IMCD cells. Systematic changes in hydrogel formulation to 
independently tune hydrogel macromer size and polymer density, adhesive ligand type and 
density, and MMP-dependent degradation revealed that each of these properties has 
profound effects on specific stages of this coordinated multicellular morphogenetic 
process, including cell viability, proliferation and tubular structure development. 
Additionally, we identified an engineered synthetic hydrogel formulation that promotes 
tubule polarization and lumen formation, integrin- and MT1-MMP-mediated growth of 
tubules, and supports continuous increase in number of tubules over time. Because of their 
inherent complexity, these new insights into the contributions of matrix biochemical and 
mechanical properties to the regulation of epithelial morphogenesis are simply not tractable 
using naturally-derived ECMs. The differences in mechanical properties that support 
IMCD tubulogenesis between naturally-derived matrices (e.g. type I collagen gels) and 
PEG-4MAL hydrogels may be elucidated by the structural and compositional differences 
of these materials. Moreover, the mechanical properties and protease degradation 
characteristics that supported murine IMCD tubulogenesis in this study are different from 
those recently identified for human renal epithelial cells125, which involved more complex, 
naturally-based hydrogels, and suggest differences between these two epithelial cell 
sources. This fully synthetic matrix addresses major limitations of naturally-derived 
materials or naturally-based hydrogels associated with lot-to-lot compositional and 
structural variability and tumor-derived nature that severely restrict scale-up applications 
and clinical translation. Furthermore, the modular nature of this hydrogel platform allows 
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Primary antibodies used were mouse anti-CFTR (A3, University of North Carolina, Chapel 
Hill) and rabbit anti-laminin (L9393, Sigma). The following secondary antibodies were 
used: goat anti-mouse IgG Alexa Fluor 647 (Thermo Fisher Scientific), and donkey anti-
rabbit IgG Dylight 649 (Thermo Fisher Scientific). Nuclei were stained with DAPI and 
filamentous actin was stained with rhodamine phalloidin (Thermo Fisher Scientific). 
Antibody dilutions were performed according to manufacturer’s instructions. 
Cell culture 
Mouse inner medullary collecting duct (IMCD) cells (isolated from αv flox/flox mice) 
where maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)/Nutrient Mixture F-
12 Ham (DMEM/F-12 50/50; D8437, SIGMA) supplemented with 10% fetal bovine serum 
(Life Technologies) and 1% Antibiotic-Antimycotic solution (MT-30-004-CI, 
MediaTech).  
Hydrogel formation and 3D cell encapsulation 
To prepare PEG hydrogels, PEG-4MAL macromer (MW 22,000 or 11,000; Laysan Bio) 
was dissolved in 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) buffer (20 
mM in DPBS, pH 7.4). Adhesive and crosslinking peptides were custom synthesized by 
AAPPTec. Adhesive peptides RGD (GRGDSPC), GFOGER (GYGGGP(GPP)5GFOGER 
 82 
(GPP)5GPC), YIGSR (CGGEGYGEGYIGSR) and RDG (GRDGSPC) were dissolved in 
HEPES at 10.0 mM (5X final ligand density) and mixed with PEG-4MAL at a 2:1 PEG-
4MAL/ligand ratio to generate functionalized PEG-4MAL precursor. Bis-cysteine 
crosslinking peptides IPES (GCRDIPES↓LRAGDRCG; ↓ denotes enzymatic cleavage 
site) or GPQ-W (GCRDGPQG↓IWGQDRCG) was dissolved in HEPES at a density 
corresponding to 1:1 maleimide/cysteine ratio after accounting for maleimide groups 
reacted with adhesive peptide. IMCD cells were resuspended at 5X final density in ice-
cold serum-free media and kept on ice. To form hydrogels, adhesive peptide-functionalized 
PEG-4MAL macromer, cells, and crosslinking peptide were polymerized for 20 min before 
addition of complete growth medium. A final density of 75,000 cells/mL were 
encapsulated in all hydrogels. Full growth medium change was performed every 2 – 3 d. 
Sample size was established as at least 4 hydrogels per condition with the premise that an 
outcome present in 4 different hydrogels under a specific condition will reveal the 
population behavior submitted to this given condition. 
Hydrogel characterization 
The storage and loss moduli of hydrogels were assessed by dynamic oscillatory strain and 
frequency sweeps performed on a MCR 302 stress-controlled rheometer (Anton Paar) with 
a 9-mm diameter, 2° cone, and plate geometry. Oscillatory frequency sweeps were used to 
examine the storage and loss moduli (ω = 0.5–100 rad s-1) at a strain of 2.31%. 
Viability and proliferation assays 
For cell viability assessment, PEG-4MAL gels were incubated in 0.5% collagenase I 
(Worthington Biochemical), 0.5 μM C12-Resazurin (live; L34951, Thermo Fisher 
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Scientific), and 1 μM TOTO-3 iodide (dead; T3604, Thermo Fisher Scientific) in serum-
free media until hydrogel was completely dissolved and cells settled at bottom of well. 
Proliferation was assayed using the Click-iT EdU Imaging Kit (C10338, Thermo Fisher 
Scientific) following manufacturer’s instructions. Samples were imaged with Nikon Plan 
Fluor 10× (NA 0.30) or Plan Fluor 20× (NA 0.45) objectives in a C2-Plus Confocal System 
(NIS Elements acquisition software). Cells were counted with ImageJ (NIH) macros. 
Immunofluorescence labeling of cysts 
Gels were washed extensively in DPBS and fixed in 4% formaldehyde in DPBS for 20 
min. Gels were incubated for 30 min in blocking buffer (1% bovine serum albumin, 1% 
goat serum, 0.1% fish skin gelatin, 0.5% Triton X-100, 0.05% sodium azide in PBS). 
Samples were incubated in primary antibodies diluted in blocking buffer on an orbital 
shaker at 4ºC overnight. Secondary antibodies and nuclear stain were diluted in blocking 
buffer and incubated on an orbital shaker at 4ºC overnight. Fluorescent images for tubule 
assessment were captured with 20X or 40X objectives in a Nikon Eclipse Ti microscope 
connected to a C2+ confocal module. Area and Feret diameter of multicellular IMCD 
structures were measured from fluorescent images of specimen cross sections using ImageJ 
macros. 
Inhibition of mediators of mechanotransduction, MMPs and integrin subunits 
Inhibition of myosin II or Rho-associated kinase was performed using blebbistatin 
(203389, Calbiochem) or Y-27632 (688002, Calbiochem), respectively, by adding 25 µM 
to the growth medium 5 d after cell encapsulation in hydrogel. Broad inhibition of matrix 
metalloproteinases (MMPs) or MT1-MMPs was performed by adding 25 µM of GM6001 
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MMP Inhibitor (CC1010, Millipore) or 200 µM of Anti-MT1-MMP antibody (AB6005, 
Millipore), respectively, to the growth medium 3 d after cell encapsulation in hydrogel. 
Inhibition of integrin subunits α1, α2 or β1 was performed by adding 0.5 µg/mL of anti-
rat/mouse CD49a (555001, BD Pharmingen), anti-rat/mouse CD49b (554998, BD 
Pharmingen) or AIIB2 (Developmental Studies Hybridoma Bank), respectively. Samples 
were imaged using a Nikon Eclipse Ti microscope connected to a C2+ confocal module.  
Statistical analyses 
Statistical analyses were performed using GraphPad Prism 6.0. For normally distributed 
data with equal variances, one-way ANOVA with Tukey’s multiple comparison test was 
used, and unpaired t-test with Welch’s correction. For non-normally distributed data, 
Krustal-Wallis with Dunn’s multiple comparisons test was used. P-values of statistical 
significance are represented as ****P < 0.0001, ***P < 0.0002, **P < 0.0021, *P < 0.0332. 
A p-value < 0. 0332 was considered significant. 
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CHAPTER 5. PEG-4MAL HYDROGELS FOR HUMAN 
ORGANOID GENERATION, CULTURE, AND IN VIVO 
DELIVERY3 
5.1 Abstract 
In vitro differentiation of human organoids (HOs) generated from embryonic stem cells 
and induced pluripotent stem cells offers unparalleled means to produce multi-cellular 3D 
structures analogous to native human tissues. Most current methods for generating HOs 
rely on MatrigelTM, a poorly defined, basement membrane derivative secreted by 
Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, limiting the potential use of HOs 
for regenerative medicine applications. Here, we describe a protocol for the synthesis of a 
fully defined, synthetic hydrogel that supports the generation and culture of HOs. Modular, 
cell-encapsulating hydrogels are formed from a four-armed poly(ethylene glycol) 
macromer having at each terminus maleimide groups (PEG-4MAL), which are conjugated 
to cysteine-containing adhesive peptides and crosslinked via protease-degradable peptides. 
The protocol also includes guidelines for the localized in vivo delivery of PEG-4MAL 
hydrogel-encapsulated HOs that support engraftment and accelerate colonic wound repair. 
This culture and delivery strategy forms a basis for the development of HO-based therapies 
to treat injury and disease. Hydrogel and tissue preparation and subsequent encapsulation 
                                                 
3 In Revision: PEG-4MAL hydrogels for human organoid generation, culture, and in vivo delivery. Cruz-
Acuña, R., Quirós, M., Huang, S., Siuda, D., Spence, J.R., Nusrat, A., and García, A.J. Nature Protocols 
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can be performed within 2.5 to 3.5 h. HOs cultured in synthetic hydrogels for at least 14 d 
can be delivered for wound repair applications in under 5 h. 
5.2 Introduction 
Human pluripotent stem cell (hPSC)-derived organoids (HOs) offer unparalleled 
strategies for generating multi-cellular 3D structures recapitulating important features of 
epithelial and mesenchymal tissue, making them valuable tools in the study of a range of 
cellular processes25,135. In this context, protocols have been developed for the in vitro 
generation of different HOs (e.g., intestine98,107, lung109,136, brain137, retina138, and 
kidney139) that provide powerful platforms to model human organ development and chronic 
diseases, for example, cancer and inflammatory bowel disease97. Furthermore, HOs can 
potentially serve as tissue sources for patient-specific regenerative therapies135. For 
example, efficient methods have been developed to direct differentiation of hPSCs into 3D 
structures (spheroids) followed by culture in specific in vitro culture conditions that enable 
the spheroids to differentiate further into human intestinal organoids (HIOs)107. As 
spheroids bud off from the pluripotent stem cell monolayer, they are initially composed of 
two multipotent cell populations, intestinal epithelial and mesenchymal populations. 
Spheroids are transferred to 3D culture where they further differentiate and expand into 
HIOs, giving rise to several different epithelial (enterocytes, goblet cells, Paneth cells, 
enteroendocrine cells, intestinal stem cells) and mesenchymal (subepithelial 
myofibroblasts, smooth muscle cells) populations. The development of HIOs has been 
shown to closely mimic the development of embryonic intestinal tissue98,104,107,140. Most 
currently available protocols for organoid generation require encapsulation of spheroids 
within biologically-derived materials, such as Matrigel™, which are not well characterized 
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and thus exhibit considerable lot-to-lot variability, poor experimental control, and the 
inability to decouple their biochemical and biophysical properties8,141,142. Additionally, in 
the case of MatrigelTM, the fact that this material is derived from murine cancerous cells 
limits its translational potential4,143. Fully defined, synthetic hydrogels that present tunable 
physicochemical properties are promising alternatives to current organoid culture 
biologically-derived matrices, as they can mediate innate cellular responses via 
presentation of bioactive motifs that promote cell-matrix adhesive interactions and cell-
directed matrix degradation127,143.  
5.2.1 Development and advantages of the protocol 
Hydrogels are water-swollen, crosslinked polymer networks with attractive 
mechanical and biochemical properties for a variety of biomedical and biotechnological 
applications4. The fully defined synthetic hydrogel system described in this protocol is 
based on a four-armed, maleimide-terminated poly(ethylene glycol) (PEG-4MAL) 
macromer that is engineered to present elements and traits inspired by extracellular 
matrices, such as cell-adhesion peptides and matrix sensitivity to cell-secreted proteases. 
Although many synthetic hydrogel systems have been developed to mimic the properties 
of natural extracellular matrices, the PEG-4MAL hydrogel platform exhibits substantial 
advantages over the other synthetic hydrogels developed thus far, including a well-defined 
structure, the stoichiometric incorporation of cell adhesive peptides (and other biological 
signals), increased cytocompatibility, and improved crosslinking efficiency9,10,127. 
Additionally, the fact that the properties of PEG-4MAL hydrogels are tunable enables the 
study of the independent contributions of the biophysical and biochemical properties of the 
matrix on both single cell and multicellular programs. For instance, using this platform, we 
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showed that normal cyst growth, polarization, and lumen formation of renal epithelial 
Madin–Darby canine kidney (MDCK) cells could only take place within a narrow range of 
values for the elasticity of the matrix, required a threshold level of cell-directed matrix 
degradability, and were subject to a tight regulation imposed by the adhesive peptide 
density9. Furthermore, we have recently reported that both the in vitro generation and 
culture of HIOs from hPSC-derived spheroids, and the culture of human lung organoids 
(HLOs), were dependent on the mechanical and biochemical properties of the PEG-4MAL 
hydrogel127. Finally, for comparison purposes, the total cost of hydrogel components 
necessary to produce a total of 10 mL of fully crosslinked synthetic hydrogel is 
approximately $140, whereas 10 mL of MatrigelTM costs approximately $305. Therefore, 
PEG-4MAL hydrogels serve as an in vitro synthetic platform that can be modulated to 
support different cellular developmental programs, like HO development, while 
overcoming the limitations of biologically-derived materials, such as MatrigelTM. 
Additionally, use of the PEG-4MAL hydrogel affords tunable reaction time scales 
for in situ gelation for in vivo applications. In fact, this synthetic hydrogel system has been 
successfully used as a delivery vehicle featuring rapid gelation and integration at the 
transplantation site. This hydrogel system has also been demonstrated to support the 
viability of encapsulated cells and to readily undergo the cell-mediated degradation that 
promotes engraftment of delivered cells into the host tissue11,144. We demonstrated that 
injection of HIOs and the liquid precursors of the hydrogel into mucosal wounds in the 
murine intestine resulted in in situ–formation of a polymerized hydrogel that supported 
localized organoid engraftment and accelerated wound repair127. Furthermore, the base 
macromer exhibits minimal toxicity and inflammation in vivo; additionally, it is rapidly 
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excreted via the urine. These are important advantageous traits to have when evaluating 
the safety and translational potential of hydrogels11. Consequently, PEG-4MAL hydrogels 
have shown to be a suitable cellular delivery tool with the potential to be used for cell-
based therapies for regenerative medicine applications. 
5.2.2 Overview of the procedure 
We describe a protocol for the synthesis of a fully synthetic PEG-4MAL hydrogel 
that supports the robust and highly reproducible in vitro generation of HOs from human 
induced pluripotent stem cell (hiPSC)- and embryonic stem cell (hESC)-derived spheroids 
that does not involve MatrigelTM encapsulation. Additionally, we provide guidelines for 
the subsequent in vitro culture and passaging of fully-developed HOs within the PEG-
4MAL hydrogel.  
Briefly, to generate hydrogels, the PEG-4MAL macromer is conjugated to an 
adhesive peptide to form a functionalized PEG-4MAL macromer (Fig. 27). The 
functionalized PEG-4MAL macromers are mixed with hPSC-derived spheroids or HOs 
and then crosslinked with a protease-degradable peptide for 20 min, before adding growth 
medium to the polymerized hydrogel (Fig 28)127. As discussed previously9,10,127, the 
macromer size (e.g., 10 kDa vs. 20 kDa) and polymer density can be modified to tune the 
density of crosslinks within the hydrogel which translates to changes in its biophysical 
properties. Moreover, the type and density of adhesive and crosslinking peptides can be 
modulated to confer specific biochemical properties onto this synthetic matrix. The ability 
to tune the biophysical and biochemical characteristics of the synthetic matrix is an 
important attribute of this platform because different cell types will respond differently to 
the biophysical and biochemical properties of their microenvironment. For example, we 
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have identified the elementary biophysical and biochemical matrix properties needed to 
support hPSC-derived organoid generation, which are different from the more 
mechanically-dynamic matrix properties needed to support the generation of organoids 
from single murine Lrg5+ intestinal stem cells143. More information regarding changes to 




Figure 27: Preparation of the solutions of the precursor of the PEG-4MAL hydrogel. 
Hydrogel precursor solutions are reconstituted in separate tubes, and functionalized PEG-
4MAL macromer is produced by mixing the solution of the PEG-4MAL macromer with 
that of the adhesive ligand. The relevant steps of the protocol are highlighted in red. 
Adapted from Cruz-Acuña and Quirós et al. (2017). 
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Figure 28: Synthesis of PEG-4MAL hydrogel and organoid generation. (a) Floating, 
hPSC-derived human spheroids (generated as previously described98,107) are collected and 
mixed with a solution of functionalized PEG-4MAL macromer. (b) PEG-4MAL hydrogel 
is casted by pipetting the mixture of functionalized PEG-4MAL and spheroids into the 
solution of the crosslinker. Encapsulated spheroids will expand and develop into human 
organoids. The relevant steps of the protocol are highlighted in red. Adapted from Cruz-
Acuña and Quirós et al. (2017). 
The present protocol also explains how to deliver hydrogel-containing HIOs 
generated in the PEG-4MAL hydrogel or a biologically-derived matrix to colonic mucosal 
wounds by injection via a colonoscope, which results in organoid survival, engraftment, 
and accelerated wound repair127. Briefly, a miniaturized colonoscope system equipped with 
biopsy forceps is used to biopsy-injure the colonic mucosa of mice (as previously 
described112,145), and to inject a HO-containing hydrogel 1 d after wounding with the aid 
of a custom-made injection device (Fig 29). The ability of this synthetic matrix to deliver 
HOs via endoscopic techniques and the minimal toxicity and inflammatory response 
associated with its use in vivo10,11 are a proof of concept that hydrogel-encapsulated HOs 
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may be used therapeutically to treat intestinal injury, overcoming the limitations associated 
with the use of MatrigelTM for HO technologies127. Moreover, the ability to tune the 
polymerization kinetics (gelling rate) of this injectable system renders possible its 
application in other settings. For example, by controlling the polymerization rate, different 
physical forms of the hydrogel can be generated such as a patch that forms on the surface 
of the heart to localize cells in rats; as an injectable matrix to deliver vasculogenic proteins 
that promote the vascularization and engraftment of pancreatic islets in rodents; or as a 
liquid drug carrier delivered via a double-lumen catheter to produce a conformal drug depot 




Figure 29: Preparation of PEG-4MAL hydrogel-generated organoids and set-up for 
mucosal injection. HIOs generated in PEG-4MAL hydrogels are recovered from the 
matrix, mixed with hydrogel precursor solutions, and injected underneath the submucosal 
wounds using a custom-made device (comprising a 10-cm piece of intramedic polyethylene 
tube with a 27G needle at each end) via a colonoscope. The relevant steps of the protocol 
are highlighted in red. Adapted from Cruz-Acuña and Quirós et al. (2017). 
5.2.3 Limitations of the protocol 
An important aspect of this engineered hydrogel platform is its rapid reaction 
kinetics that may result, if mixing is not conducted properly, in the formation of an 
inhomogeneous gel that presents variabilities in its physicochemical properties. Therefore, 
to avoid inhomogeneities in the hydrogel properties due to premature crosslinking, the 
functionalized macromer and crosslinker solutions may need to be delivered separately and 
mixed at the in vivo delivery site, or mixed prior to rapid delivery into the in vivo site. 
Furthermore, for adhesive ligands and crosslinking peptides to be incorporated into PEG-
4MAL hydrogels, these molecules must have free thiol groups that can react with the 
maleimide moieties of the hydrogel backbone. Therefore, these signaling sequences might 
need to be custom-synthesized to contain a free thiol group (e.g., a cysteine residue) that 
enables the chemical coupling into PEG-4MAL hydrogels to take place. 
5.2.4 Application and extension of the method for human organoid generation and 
delivery 
 The PEG-4MAL hydrogel system serves as a robust platform for the in vitro 
generation and culture of different types of HOs that facilitates the study of the 
contributions of the extracellular matrix to human organ development, differentiation, and 
function. For this purpose, we reported an engineered hydrogel (storage modulus (G’): 100 
Pa; 4.0%, 20 kDa PEG-4MAL; 2.0 mM RGD; GPQ-W crosslinker) that supports the in 
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vitro generation of HIOs from hPSC-derived spheroids and culture of HLOs109, 
establishing its potential to generate and maintain different types of HOs127. The modular 
design of the PEG-4MAL hydrogel system provides the means to independently optimize 
the physicochemical properties of the synthetic matrix to identify the engineered 
formulation that supports HO generation. For instance, we demonstrated9,10,127 that the 
mechanical properties of the synthetic matrix can be controlled by varying the polymer 
density, independently from the matrix’s biochemical properties (adhesive peptide type or 
density). Conversely, the biochemical characteristics of the material can be modified by 
changes in the adhesive peptide type (e.g. laminin- or collagen-derived peptides) or density, 
independently from the material’s mechanical properties. These modifications of the 
matrix properties were proven to have a direct effect on the epithelial morphogenesis of 
different cell systems and on spheroid development into HIOs9,127. Therefore, in addition 
to the inherent potential of the engineered hydrogel, its modular design supports the 
adaptability of this synthetic material to assist with the generation and culture of different 
types of HOs. 
 Furthermore, we have established that the engineered hydrogel can be used as a 
HIO delivery vehicle to mucosal wounds that supports localized organoid engraftment and 
accelerated wound repair127. We also demonstrated that the presence of the delivery 
hydrogel is required for HIO engraftment at the implantation site127. Therefore, this 
delivery strategy may be the starting point for the development of HO-based tissue 
replacement therapies that are based on the direct engraftment into injured or diseased 
organs, for example as an approach to treat human gastrointestinal diseases associated with 
intestinal epithelial wounds (e.g. inflammatory bowel disease). 
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5.3 Experimental Design 
PEG-4MAL hydrogels have previously demonstrated to be a reproducible platform 
for the in vitro generation and in vivo delivery of HOs127. The reproducibility of the 
synthetic hydrogel has been established with a sample size of at least 4 hydrogels per 
condition (20-30 spheroids/hydrogel or 2-4 HOs/hydrogel) for in vitro experimentation, 
and 4 mice per condition (4–5 injections per mouse) for in vivo experimentation, with the 
premise that an outcome present in all hydrogels or animals under a specific condition will 
reveal the population behavior submitted to this given condition127. Additionally, for a 
particular hydrogel formulation, consistent biophysical and biochemical properties, as well 
as the resulting spheroid/HO responses, have been observed across independent 
experimental runs performed on different days, demonstrating high reproducibility. For all 
in vitro experiments, if making more than one functionalized PEG-4MAL precursor 
solution, it is recommended to allocate all human spheroid or HO suspension in one tube 
(as indicated in the protocol) and ensure proper mixing prior to mixing with the hydrogel 
precursor solutions, to ensure a random distribution of the biological tissue. No specific 
randomization scheme is recommended for in vivo delivery of HOs, although 
randomization of samples is highly recommended. Finally, to avoid research bias, it is 
recommended that the researcher(s) performing the experiments is(are) different from the 
researcher(s) processing and analyzing the experimental results. 
5.3.1 Synthetic hydrogels for hPSC-derived spheroids and HOs 
Efficient methods have been developed to generate HOs from in vitro hPSC 
cultures through direct differentiation protocols that are specific to the developmental 
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program of the tissue origin of interest135. During the initial differentiation stages of hPSCs, 
human spheroids arise by budding from the hPSC monolayer and detaching. To generate 
the HOs, the detached, floating spheroids are collected and transferred to 3D culture, most 
commonly in Matrigel™, where they further differentiate and expand into HOs, giving rise 
to several differentiated tissue-specific cellular populations. The generated HOs can be 
further cultured and undergo passaging in the 3D culture environment for research 
purposes that encompass studying organ development and tissue-specific disease 
progression135. Nevertheless, biologically-derived, 3D culture environments exhibit 
considerable lot-to-lot variability, the inability to decouple its biochemical and biophysical 
properties8,141,142, and in the case of MatrigelTM, the fact that it is derived from murine 
cancerous cells limits its translational potential4,143. Consequently, fully defined, PEG-
4MAL hydrogels that present tunable physicochemical properties have demonstrated to be 
a promising alternative to current organoid culture matrices for translational medicine 
applications127. 
This protocol provides guidelines to engineer a PEG-4MAL hydrogel for the in 
vitro generation of the desired HO by substituting the use of MatrigelTM on the 
encapsulation of floating 3D spheroids generated from hPSC cultures by directed 
differentiation (e.g. midgut and hindgut spheroids for generation of HIOs, as previously 
described98,107,127). Additionally, the synthetic matrix can be used for the continuous 3D 
culture and passaging of hPSC-derived human organoids that were generated using the 
synthetic material or using MatrigelTM (e.g., HIOs generated in MatrigelTM for at least 14 
d, as previously described98,107,127). Moreover, because this protocol is intended for the 
generation and culture of hPSC-derived HOs, the passaging steps provided here differ from 
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trypsin-based passage protocols used for primary tissue-derived organoids142,148. For 
instance, due to the mesenchymal layer and the large size of HIOs, these cannot be 
passaged in a manner similar to organoids derived from primary tissue and required manual 
cutting107, as described in this protocol. We emphasize that manual cutting has been 
previously reported for HIO cultures in MatrigelTM,(107) and thus the procedure and time 
required to manually cut organoids into halves is independent of the matrix used and does 
not represent a limitation of the synthetic hydrogel. For hPSC-derived human organoids 
that do not require manual cutting, such as HLOs109, this specific step can be skipped. 
5.3.2 Synthetic hydrogels can be adapted for different HO systems 
An attractive feature of the PEG-4MAL hydrogel system is the ability to 
independently tune its biophysical and biochemical properties, which allows for its 
adaptation to the culture of different types of HOs. The macromer size (e.g., 10 kDa vs. 20 
kDa) and polymer density can be modified to tune the density of crosslinks within the 
hydrogel, which translates to changes in its biophysical properties; moreover, the type and 
density of adhesive and crosslinking peptides can be modulated to confer specific 
biochemical properties onto this synthetic matrix. For instance, variations to the PEG-
4MAL polymer density directly controls its stiffness9,10,127 (storage modulus, G’; 
biophysical property), independently from its adhesive peptide type and density (2.0 mM 
RGD, biochemical property) (Fig. 30). Given a constant adhesive peptide concentration, 
when the PEG-4MAL polymer density is increased (decreased), the number of additional 
(fewer) maleimide moieties must be compensated by a higher (lower) concentration of 
crosslinks (e.g. GPQ-W crosslinking peptide) which in turn increases (decreases) the 
matrix stiffness. Therefore, in this hydrogel system, the mechanical properties (e.g., elastic 
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modulus, or the related storage modulus determined by rheometry) are determined by the 
density of crosslinks in the hydrogel network. Matrix stiffness is an important biophysical 
property to consider when designing a synthetic cellular matrix for the type of HO of 
interest, as we have previously shown that different biophysical cues (4% and 6% PEG-
4MAL polymer density, Fig. 30) support the morphogenesis program of different epithelial 
cell lines (MDCK and Caco-2, respectively)9. Therefore, PEG-4MAL polymer density can 
be modified to tune the density of crosslinks and identify a matrix stiffness that provides 
the physical support and promotes the essential mechanosignals for the generation and 
culture of the HO of interest. For reference, we have previously shown that PEG-4MAL 
polymer density controls HIO generation from hPSC-derived intestinal spheroids and 
influences the prolonged viability of HIOs generated in MatrigelTM,127. 
 
Figure 30: Typical results of rheometric characterization of PEG-4MAL hydrogels. 
Relationship between polymer density (wt%) and storage modulus of 20 kDa PEG-4MAL 
hydrogels with constant biochemical properties (2.0 mM RGD, using GPQ-W crosslinker). 
Data is presented as mean ± SEM; n = 4 independently prepared hydrogels per condition. 
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The functionalization of the PEG-4MAL macromer using adhesive peptides is an 
important biochemical property to consider when designing a synthetic cellular matrix that 
best resembles the biochemical environment of the native tissue of interest4. In this context, 
given a constant density of PEG-4MAL, the hydrogel macromer can be functionalized with 
different types and densities of cysteine-terminated adhesive peptides (e.g. RGD, laminin-
, or collagen-derived peptides) to modify the biochemical characteristics of the material, 
considering that all unreacted maleimide groups remaining are crosslinked. For reference, 
we have previously shown that the adhesive peptide type has a significant effect on HIO 
viability127, and that adhesive peptide (RGD) density dramatically regulates cyst polarity 
and lumen phenotypes of epithelial cells9. Finally, the capacity of cells to modify their 
microenvironment via matrix degradation is essential for tissue remodeling and 
homeostasis4,149. In this context, given a constant density of PEG-4MAL and a fixed type 
and density of adhesive peptide, the level of hydrogel degradability by proteases can be 
modulated by varying the ratio between a relatively fast-degrading (e.g. GPQ-W) and a 
slow- or non-degrading (e.g. GPQ-A9 or DTT127, respectively) crosslinking agent. 
Therefore, when designing a PEG-4MAL hydrogel matrix for the HO of interest, it is 
important to consider the use of a crosslinking peptide that is sensitive to the proteases 
expressed by the HO. We have previously demonstrated that prolonged survival of HIOs 
requires a degradable matrix crosslinked with the collagen-derived GPQ-W peptide127, and 
that normal epithelial cyst polarity and lumen formation required a threshold level (80% 
fast-degrading GPQ-W) of protease-directed matrix degradability9. Finally, as in a 
previous report, users can evaluate the suitability of the synthetic hydrogel for the 
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generation of HIOs by assessing human intestinal spheroid/HIO viability at different time 
points, proliferation, growth and morphological changes of the HIO structure127. 
This protocol describes a synthetic hydrogel platform that can be established to 
support the in vitro generation and culture of different types of HOs via modulation of its 
biophysical and biochemical matrix properties, as described. Furthermore, this protocol 
provides guidelines (Box 1) to generate an engineered hydrogel formulation (storage 
modulus (G’): 100 Pa; 4.0%, 20 kDa PEG-4MAL; 2.0 mM RGD; GPQ-W crosslinker) that 
supports the in vitro generation of HIOs from hPSC-derived spheroids and culture of 
HLOs127. Therefore, this engineered formulation should be used as a starting point for 
designing a PEG-4MAL hydrogel for the in vitro generation and culture of the HO of 
interest. Further variations to the biophysical and biochemical matrix properties described 
above can be explored if the initial hydrogel formulation (Box 1) does not support the 
viability and growth of the human spheroid/HO of interest. Further discussion regarding 
variations to the biophysical and biochemical matrix properties is presented in Box 1. 
5.3.3 Murine model for HIO transplant into colonic wounds 
Another attractive feature of the PEG-4MAL hydrogel platform is that it affords 
tunable reaction time scales for in situ gelation for in vivo applications. For example, 
adjusting the pH of the hydrogel precursor solutions to slightly below physiological pH 
(6.5–7.4) will reduce the reaction kinetics. Reducing the speed of reaction can help prevent 
premature crosslinking that may occur during hydrogel delivery via custom-made devices, 
such as the injection device described later (Fig. 29). 
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We provide a procedure to develop a custom-made device for the injection of HIOs 
and the liquid precursors of the hydrogel through a colonoscope into murine mucosal 
wounds resulting in in situ–formation of a polymerized hydrogel at the injection site. We 
recommend the use of NOD-scid IL2Rg-null (NSG) mice as recipients for transplantation 
of human organoids using synthetic hydrogels to minimize immune rejection by the host 
to transplanted human tissue. NSG mice have demonstrated to be consistently better for 
human stem cell engraftment as compared to several other immunocompromised mouse 
strains150. We recommend male animals around 12 weeks old as male mice have longer 
colons than females, providing more space for colonoscopy purposes. At 12 weeks old, 
mice are less susceptible to suffer intestinal perforations as a consequence of the biopsy 
injury and have optimal repair programming. Nevertheless, we have conducted studies with 
C57BL/B6 mice at different ages and found no differences in wound repair between 3 
months old up to 1 year old. We have previously used 8-week old, male NSG mice as a 
proof of concept for the use of the synthetic hydrogel as a delivery vehicle for HIOs to 
murine colonic wounds using a colonoscope, promoting HIO engraftment and accelerated 
wound healing127.  
5.4 Materials 
REAGENTS 
• PEG-4MAL macromer (MW 22,000, >95% MAL functionalization; Laysan Bio, Cat. 
No. 4arm-PEG-MAL-20K) 
• RGD: GRGDSPC (AAPPTec, custom synthesis, purity: > 95%, TFA removal) 
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• GPQ-W: GCRDGPQGIWGQDRCG (AAPPTec, custom synthesis, purity: > 95%, 
TFA removal) 
• Human spheroid derived from hESCs (we have used H9 [NIH registry #0062] and 
derived these to human intestinal spheroids as described in ref98,107), human spheroid 
derived from hiPSCs (we have used line 20.1, generated by the Pluripotent Stem Cell 
Facility, Cincinnati Children’s Hospital Medical Center98, and derived these to human 
intestinal spheroids as described in ref98,107), HIOs derived from an hESC (we have 
used H9; NIH registry #0062; we derived these as described in ref98,107), HIOs derived 
from an hiPSC (we have used line 20.1; generated by the Pluripotent Stem Cell Facility, 
Cincinnati Children’s Hospital Medical Center98; we derived these as described in 
ref98,107), or HLOs derived from hESC (UM63-1; NIH registry #0277; we derived these 
as described in ref 109) 
CAUTION:   We regularly monitor stem cell lines for chromosomal karyotype. For this 
purpose, the number of chromosomes are confirmed, chromosomal abnormalities are ruled 
out and sex chromosomes of each line are confirmed. Assessment of functional and 
molecular authentication for pluripotency and for the ability of the cells to undergo multi-
lineage differentiation is performed using a panel of antibody and qRT-PCR markers. 
• Advanced DMEM-F12 medium (Invitrogen, Cat. No. 12634-010) 
• L-Glutamine (100×; Invitrogen, Cat. No. 25030-081) 
• Penicillin–streptomycin (100×; Invitrogen, Cat. No. 15140-122) 
• B27 supplement (50×; Invitrogen, Cat. No. 17504044) 
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• N-2 supplement (100×; Gibco; Cat. No. 17502048) 
• Fetal bovine serum (FBS; Life Technologies, Cat. No. 16000-044) 
• Noggin (R&D Systems, Cat. No. 6057-NG) 
• R-spondin1 (R&D Systems, Cat. No. 4645-RS) 
• Epidermal growth factor (EGF; R&D Systems, Cat. No. 236-EG) 
• Fibroblast growth factor 10 (FGF-10; R&D Systems, Cat. No. 345-FG-025/CF) 
• HEPES solution (Sigma, Cat. No. H0887) 
• DPBS (Thermo Fisher Scientific, Cat. No. 14040133) 
• MatrigelTM (BD Biosciences, Cat. No. 354234) 
• Recipient mice for transplant of organoids.  We recommend the use of 12-week old, 
male NOD-scid IL2Rg-null (NSG) mice for the example application we describe in the 
procedure (Jackson Laboratory) 
Caution: All animal studies must be reviewed and approved by the relevant animal care 
committees and must conform to all relevant institutional and national ethics regulations. 
The method we describe here was approved by University of Michigan’s Institutional 
Animal Care and Use Committee (IACUC) in accordance with the U.S. Department of 
Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) regulations and 
the National Institutes of Health (NIH) Office of Laboratory Animal Welfare (OLAW) 
regulations governing the use of vertebrate animals. 
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• Ketamine-HCL (Hospira, Cat. No. RL-3760) 
• Xylazine (Lloyd laboratories, Cat. No. 4811) 
 
EQUIPMENT 
• Stereomicroscope (Olympus SZ61) 
• Horizontal clean bench (Labcono) 
• Costar® multi-well ultra-low attachment plate (Corning, Cat. No. 3473; 24-well plate, 
recommended) 
• Costar® Spin-X Centrifuge Tubes (Cole-Palmer, Cat. No. UX-01937-32) 
• Microcentrifuge tubes (VWR, Cat. No. 10025-724) 
• High-precision analytical balance (Mettler Toledo, Cat. No. XPE105, or equivalent) 
• pH bench meter (Mettler Toledo, Cat. No. SC S220-B) 
• MI-410 Combination pH microprobe (Microelectrodes, Inc.), or equivalent 
• Microcentrifuge (Beckman Coulter, Cat. No. B30137) 
• Large orifice pipette tips (USA Scientific, Cat. No. 1011-8410 and 1011-9410) 
• Forceps and/or tungsten needle 
• Disposable scalpel (size 15; Exelint, cat. no. 29556) 
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• Colonoscope (Mainz Coloview® Veterinary Endoscope, Karl Storz) 
• Biopsy forceps (Mainz Coloview® Veterinary Endoscope, Karl Storz) 
• 27G needles (BD, Cat. No. 305109) 
• TB syringes (BD, Cat. No. 309659) 
• Polyethylene tubing (Bector Dickinson, Cat. No. 427406) 
• Plastic feeding (gavage) needles (Instech, Cat. No. GTP-20-30-50) 
• 10 mL syringes (BD, Cat. No. 309604) 
 
REAGENT SETUP 
20 mM HEPES buffer, pH 7.4. To prepare 100 mL of 20 mM HEPES buffer, mix 2 mL 
of HEPES solution with 90 mL of DPBS. Adjust the pH to 7.4 using 6 M NaOH and adjust 
the volume of the resulting solution to 100 mL with DPBS. Sterile 20 mM HEPES buffer 
can be stored for 2 months at room temperature. 
Intestine growth medium. For 500 mL of intestine growth medium, pool together 459.7 
mL of advanced DMEM-F12 medium, 5 mL of L-glutamine (final concentration, 2 mM), 
7.5 mL of HEPES solution (final concentration, 15 mM), 20 mL of B27 supplement (1X 
final dilution = 2 mL per 50 mL of medium), 5 mL of penicillin–streptomycin (final 
concentration, 100 U/mL penicillin, and 100 µg/mL streptomycin), 200 µL of Noggin 
(250µg/mL; final concentration, 100 ng/mL), 100 µL of EGF (500 µg/mL; final 
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concentration, 100 ng/mL), and 2.5 mL of R-Spondin1 (100µg/mL; final concentration, 
500 ng/mL). The intestine growth medium is best if freshly made, but can be stored for 1 
week at 4 oC. 
Foregut basal medium. For 500 mL of foregut basal medium, pool together 470 mL of 
advanced DMEM-F12 medium, 5 mL of L-glutamine (final concentration, 2 mM), 5 mL 
of HEPES solution (final concentration, 10 mM), 5 mL of penicillin–streptomycin (final 
concentration, 100 U/mL penicillin, and 100 µg/mL streptomycin), 10 mL of B27 
supplement (1X final dilution = 1 mL per 50 mL of medium), 5 mL of N-2 supplement (1X 
final dilution = 0.5 mL per 50 mL of medium). This Foregut basal medium can be stored 
at 4ºC for up to 1 month. 
Human lung organoid growth medium. On the day of use, aliquot 49.5 mL of foregut 
basal medium into a 50 mL conical tube. Add 500 µL of FBS (final concentration, 1%) and 
250 µL of FGF-10 (100µg/mL stock; final concentration, 500 ng/mL). The human lung 
organoid growth medium is best if freshly made, but can be stored for 1 week at 4 °C. 
Anesthesia solution. Prepare anesthesia solution by diluting ketamine and xylazine in 
DPBS in a 1:1 ratio of ketamine 20 mg/mL and xylazine 2 mg/mL dilution. Prepare 
solution considering that 1 mL of anesthesia solution is needed per 0.1 kg of murine body 
weight. Prepare this solution fresh every time.  
Hydrogel components. Aliquot each hydrogel component. We aliquote PEG-4MAL 
macromer, RGD, and GPQ-W peptides (powder) in 100 mg, 25 mg and 50 mg aliquots, 
respectively, to avoid humidity exposure caused by the components experiencing multiple 
temperature changes. We also recommend to dissolve the necessary amount of hydrogel 
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components on the same day of experimentation. We do not recommend dissolving and 
then storing the PEG-4MAL macromer, as the maleimide groups may hydrolyze. 
CRITICAL: Upon receipt, immediately store PEG-4MAL macromer, RGD, and GPQ-W 
peptides (powder) at -20 oC. 
Custom-made device for injections. Remove the metalic needle of a 27G needle (OD: 
0.41 mm) from the hub. Carefully attach the blunt end of the needle to one end of a 10 cm 
piece of intramedic polyethylene tube (OD: 1.09 mm), leaving the needle bevel exposed. 
Connect another complete neddle to the other end of the tube through the needle bevel (Fig. 
29). Prepare one custom-made device for each injection to avoid clogging. We recommend 
to prepare the custom-made device before starting the experimental procedure described in 
Step 13B. 
5.5 Procedure 
5.5.1 Preparation of hydrogel precursor solutions 
1. Allow an aliquot of PEG-4MAL macromer, adhesive peptide (RGD) and crosslinker 
(GPQ-W) to reach room temperature (~20 oC). 
2. Weigh out 100.0 mg of PEG-4MAL macromer, 4.06 mg of RGD and 13.27 mg of 
GPQ-W using a high-precision analytical balance and place each component into a 
separate microcentrifuge tube (see Box 1 for sample calculation). 
Critical step: This amount of hydrogel precursors produces a total of 2.5 mL hydrogel 
volume of 4.0% (wt./vol.), 20 kDa PEG-4MAL hydrogels (G’: 100 Pa) functionalized with 
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2.0 mM RGD and crosslinked with GPQ-W peptide. This specific hydrogel formulation 
was previously reported for HIO generation and HLO culture127, and thus serves as a 
starting point to identify a hydrogel formulation for the generation and culture of the HO 
of interest. 
Critical step: Variations to the biophysical and biochemical matrix properties can be 
explored if the hydrogel formulation described here does not support the viability and 
growth of the human spheroid/HO of interest. These changes may change the values used 
in this example but do not change the steps described in this protocol. Please refer to Box 
1 for further information. 
3. Dissolve the GPQ-W and RGD peptides using 0.5 mL of 20 mM HEPES buffer for 
each peptide to produce 15.57 mM and 11.76 mM peptide solutions, respectively, after 
considering the purity of the peptides (as demonstrated in Box 1). 
Critical step: Adjust the pH of each peptide solution to 7.4 using 6 M NaOH, while 
measuring pH using a pH meter combined with a pH microprobe. 
Critical step: These RGD and GPQ-W peptide concentrations correspond to 5 times the 
concentration of their final density (see Box 1 for example calculation). This concentration 
factor can be changed given that all maleimide groups of the PEG-4MAL are conjugated 
after all hydrogel components are mixed. 
4. Filter RGD solution (prepared in step 3), GPQ-W solution (prepared in step 3) and 1 
mL of 20 mM HEPES buffer by transferring each solution to a separate Costar Spin-X 
centrifuge tube and centrifuge each tube at 9,000 g for 1 min at room temperature. 
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5. Dissolve the PEG-4MAL macromer using 1 mL of 20 mM HEPES buffer filtered in 
step 4 to produce a 4.55 mM solution (Fig. 27). 
Critical step: This PEG-4MAL macromer concentration corresponds to 2.5 times the 
concentration of its final density (see Box 1 for example calculation). This concentration 
factor can be changed given that all maleimide groups of the PEG-4MAL are conjugated 
after all hydrogel components are mixed. (see Box 1 for example calculation). 
Critical step: Steps 5–13 must be performed in a sterile environment (e.g. using a horizontal 
clean bench and sterile tools). 
6. Mix the solutions of PEG-4MAL macromer and adhesive peptide (RGD) in a 2:1 PEG-
4MAL/adhesive peptide volume ratio (1.0 mL of PEG-4MAL macromer and 0.5 mL 
of RGD peptide for this example) to generate the solution of the functionalized PEG-
4MAL precursor. Incubate then the solution thus obtained for at least 15 min at 37 oC 
(Fig. 27).  
Critical step: This step produces the conjugation between the maleimide groups of the 
PEG-4MAL and the thiol groups of the peptides. 
Critical step: The solution can be then stored at room temperature for no more than 3 h to 
avoid hydrolyzation of the maleimide groups, and to allow time to complete the next step. 
7. Prepare a hPSC-derived 3D spheroid (option A), or hPSC-derived HO (option B) 
suspension in a separate microcentrifuge tube. 
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Critical step: This step applies to (option A) any type of hPSC-derived 3D spheroids 
generated in vitro by directed differentiation protocols (e.g. midgut and hindgut spheroids 
for generation of HIOs, as previously described98,107) with the purpose of generating HOs, 
or (option B) any type of hPSC-derived HO that was generated in MatrigelTM for a period 
of time established by its differentiation protocol (e.g. HIOs and HLOs generated in 
MatrigelTM for at least 14 d, as previously described98,107,109,127) or similar matrix. 
 
A. Preparation of a human spheroid suspension (Timing: 30 min) 
i. Harvest floating hiPSC- or hESC-derived spheroids that have reached the desired 
differentiation stage (e.g. midgut and hindgut spheroids present in the cultures on 
day 4 and day 5 of mid/hindgut induction as previously described98,107) by pipetting 
with large orifice pipette tips, and transfer them to a microcentrifuge tube 
containing growth medium (Fig. 28a). 
ii. Adjust the volume of the spheroid suspension using growth medium (to a total 
volume of at least 0.5 mL for this example) to obtain a spheroid density that 
corresponds to 5 times the concentration of their final density in the hydrogels, and 
keep on ice (Fig. 28a). We recommend a final density of 20–30 spheroids per 40 
µL of hydrogel and to not store the spheroid solution in ice for longer than 1 h, as 
previously reported for intestinal spheroids127. 
B. Preparation of a human organoid suspension (Timing: 30 min) 
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i. Mechanically dislodge HOs generated in MatrigelTM (e.g. HIOs and HLOs, as 
previously described98,107,109,127) or a similar matrix by vigorously pipetting the 
matrix with large orifice pipette tips to free the organoids, and transfer them to a 
microcentrifuge tube containing growth medium. 
We have used HIOs and HLOs that have been generated from MatrigelTM-encapsulated 
spheroids for at least 14 d (as previosuly reported127), although it is likely that other types 
of hPSC-derived HOs that were generated in MatrigelTM or similar matrix for a different 
time frame can be used. 
ii. Adjust the volume of the HO suspension using growth medium (for this example, 
to a total volume of at least 0.5 mL) to obtain a HO density that corresponds to 5 
times the concentration of their final density in the hydrogels, and keep on ice. We 
recommend a final density of 2–4 HOs per 40 µL of hydrogel and to not store the 
HO solution in ice for longer than 1 h, as previously reported for HIOs and HLOs127. 
5.5.2 Synthetic hydrogel casting 
8. Mix the human spheroid suspension or the HO suspension with the functionalized 
PEG-4MAL precursor solution (prepared in step 6) at a 3:1 functionalized PEG-
4MAL/cell suspension volume ratio (for this example, 1.5 mL of functionalized PEG-
4MAL precursor and 0.5 mL of human spheroid suspension or HO suspension) using 
large orifice pipette tips, and keep on ice for no longer than 30 min (Fig. 28a). 
9. Add crosslinking peptide solution (GPQ-W) prepared in Step 4 (20% of desired final 
hydrogel volume, as shown in Box 1 — we recommend adding 8 μL of GPQ-W to 
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each well, to produce 40 μL of hydrogel in each well) to the bottom (centered) of 
each well of a multi-well plate (Fig. 28b). 
Critical step: Perform this step in the shortest time possible to avoid crosslinker 
evaporation. 
10. Pipette the mixture comprising the functionalized PEG-4MAL precursor and the cell 
mixture prepared in Step 8 (80% of desired final hydrogel volume, as shown in Box 1 
— as mentioned in the previous step, we recommend adding 32 μL of this solution, to 
produce 40 μL of hydrogel in each well) into the crosslinker solution in each well 
using large orifice pipette tips (Fig. 28b). 
Critical step: Mix the solution by pipetting several times to obtain a homogenous 
solution. Critical step: Use a new pipette tip to cast each different hydrogel. 
Critical step: Perform this step in the shortest time possible to avoid crosslinker 
evaporation. 
11. Allow the hydrogel to form by incubating the plate at 37 oC for 20 min. 
? Troubleshooting 
Overlay each hydrogel with 500 µL of medium (e.g. intestine growth medium for intestinal 
spheroids or HIOs, or human lung organoid growth medium for HLOs), ensuring that the 
hydrogel is covered by medium. Replace the medium every 4 d, or when the phenol red 
(included in the Advanced DMEM-F12 medium) in the medium turns yellow (Fig. 28b). 
5.5.3 Organoid generation/culture and delivery 
12. Passage human spheroids or HOs encapsulated in PEG-4MAL hydrogels every 7–10 
days (option A), and continue the culture for the desired time frame. If generating HIOs 
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or culturing HIOs generated in a different matrix, these can then be delivered with 
synthetic hydrogel precursor solutions via injection into a colonic wound (option B). 
Critical point: The hydrogel degradation, and thus, the frequency of passages may vary 
according to the type and density of encapsulated spheroids/HOs within the hydrogel. 
Proceed to passage human spheroids/HOs when these starts to settle to the bottom of the 
well of the culture plate. 
Critical point: The culture timeframe of human spheroids can vary according to its type 
and its timeline of expansion into HO. For reference, we allow at least 14 d of expansion 
of encapsulated intestinal spheroids into HIOs (Fig. 28b), and we have successfully 
passaged HIOs for up to 3 passages, spanning approximately 21 d, stopping only for an 
experimental endpoint, as previously reported127. It is likely that HIOs will continue to 
grow and expand for a much longer period than the mentioned 21 d. 
? Troubleshooting 
A. Organoid passaging (Timing: Variable) 
Critical step: Organoid passaging as described here is intended for hPSC-derived HOs and 
differs from the trypsin-based passage protocols used for primary tissue-derived organoids. 
i. Repeat Steps 1–6 (“Preparation of hydrogel precursor solutions”) to prepare the 
hydrogel precursor solutions needed to make new hydrogels. 
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ii. Mechanically dislodge organoids from the PEG-4MAL hydrogel by vigorously 
pipetting the hydrogel with large orifice pipette tips to free the organoids from 
the matrix. 
iii. Pool all the hydrogel + organoids + medium from each well into a sterile Petri 
dish containing 10 mL of warm advanced DMEM-F12 medium. By using a 
sterile tungsten needle or sterile fine forceps, dislodge any large pieces of 
hydrogel that still adhere to the organoids. 
iv. Under a stereomicroscope, manually cut the organoids into halves using a 
scalpel. 
Critical step: This step is only required for HOs that have been previously reported to 
require manual cutting during passaging. For example, manual cutting is required for 
HIOs107 due to the mesenchymal layer present and large size. For other types of HOs that 
do not require manual cutting, such as HLOs109, this step can be skipped. 
v. Transfer organoid to a microcentrifuge tube, and adjust the volume of the 
suspension using growth medium (for this example, to a total volume of at least 
0.5 mL) to obtain a HO density that corresponds to 5 times the concentration of 
their final density in the hydrogels, and keep on ice. We recommend a final 
density of 2–4 HOs per 40 µL of hydrogel and to not store the HO solution in 
ice for longer than 1 h, as previously reported for HIOs and HLOs127. 
vi. Repeat Steps 8–13 (“Synthetic hydrogel casting”) using the organoid 
suspension prepared in step 13A v, to form new HO-containing hydrogels. 
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B. Organoid encapsulation and injection into colonic mucosal wound bed (Timing: 5 h) 
Critical step: Organoid encapsulation and injection into colonic mucosal wound beds as 
described here is recommended for hPSC-derived HIOs generated in the PEG-4MAL 
hydrogel or MatrigelTM, as previously demonstrated127. 
i. One day before injection, mechanically induce mucosal wounds in recipient mice, 
as previously described145. We use NOD-scid IL2Rg-null (NSG) mice and use 
biopsy forceps to induce injury. Briefly, we introduce the biopsy forceps through 
the auxiliary pocket until the tip of the forceps is observed through the high-
resolution colonoscope camera. We then carefully make 4–5 wounds of ~1 mm in 
diameter in the colonic mucosa of each mouse, as previously reported127,145.  
Caution: All animal studies must be reviewed and approved by the relevant animal 
care committees and must conform to all relevant institutional and national ethics 
regulations.  
ii. Repeat Steps 1–6 (“Preparation of hydrogel precursor solutions”) to prepare the 
hydrogel precursor solutions needed to make new 4% PEG-4MAL hydrogels 
functionalized with 2.0 mM RGD and crosslinked with GPQ-W peptide for the 
injections (Fig. 27; Box 1). We have previously reported that this hydrogel 
formulation promotes HIO engraftment into host tissue and accelerated wound 
repair127. 
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iii. Mechanically dislodge from the matrix HIOs generated within PEG-4MAL 
hydrogels (as described above) or MatrigelTM (as previously described98,107,127) by 
vigorously pipetting with large orifice pipette tips to free the organoids (Fig. 29). 
iv. Transfer HIOs to a microcentrifuge tube, and adjust the volume of the suspension 
using intestine growth medium (for this example, to a total volume of at least 0.5 
mL) to obtain a HIO density that corresponds to 5 times the concentration of their 
final density in the hydrogels, and keep on ice. We recommend a final density of 
10 HIOs per 50 µL of hydrogel and to not store the HIO solution in ice for longer 
than 1 h, as previously reported127 (Fig. 29).  
v. Load 10 µL of the crosslinker solution onto the custom-made device, whose 
preparation is described in the Equipment setup.  
Critical step: One custom-made device is needed for each injection to avoid 
clogging. 
vi. Mix the HIO suspension prepared in step 13B iv with the PEG-4MAL-RGD 
precursor solution prepared in step 13B ii in a 3:1 PEG-4MAL-RGD/HIO 
suspension volume ratio (for this example, 1.5 mL of functionalized PEG-4MAL 
precursor and 0.5 mL of HIO suspension) using large orifice pipette tips and keep 
the resulting mixture on ice for the duration of the following steps (Fig. 29). 
vii. Load the PEG-4MAL-RGD precursor + HIO mixture solution prepared in the 
previous step in a 1-mL TB syringe. Please note that 40 µL of this solution will be 
used per injection (Fig. 29).  
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viii. Connect the custom-made device containing the crosslinker solution (see step 13B 
v) to the TB syringe containing the PEG-4MAL-RGD + HIO suspension (Fig. 29). 
Insert the nedle bevel through the colonoscope forceps auxiliary pocket. 
ix. Anesthetize mice by intraperitoneal injection of the anesthesia solution (1 mL/kg). 
Ensure that the mouse is adequately anesthetized by testing its pedal reflex and 
monitoring its respiration. 
x. Use DPBS in a plastic gavage neddle to lubricate and insert the colonoscope probe 
into the rectum. Use a colonoscope equipped with a high-resolution camera to 
identify the mucosal wounds. 
xi. Once a wound has been found, position the colonoscope probe close to the distal 
end of the wound. Push the tubing through the auxiliary pocket until the needle 
bevel is observed through the camera and proceed to carefully penetrate the mucosa 
and locate the needle bevel right at the wound bed (as demonstrated previously145; 
Fig. 29, Fig. 31). 
xii. Inject 40 µL of the functionalized PEG-4MAL-RGD + HIO suspension, which will 
mix with the crosslinker solution in the tubing, leading to the in situ formation of 
the hydrogel at the injection site. Monitor the success of the procedure by checking 
to see that small, yet visible, protrusion appears at the injection site (as 
demonstrated previously145). 
? Troubleshooting 
xiii. Pull the needle out and repeat injections at a different wound site if required. 
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Critical step: We recommend performing one injection per wound to avoid risk of 
perforation. 




Steps 1–6, Preparation of hydrogel precursor solutions: 1–2 h 
Step 7A, Preparation of human spheroid suspension: 30 min 
Step 7B, Preparation of human organoid suspension: 30 min 
Steps 8–12, Synthetic hydrogel casting: 1 h 
Step 13, Organoid culture and delivery: Variable 
Step 13A, Organoid passaging: Variable 
Step 13B, Organoid encapsulation and injection into colonic mucosal wound bed: 5 hr 
 
Figure 31: PEG-4MAL hydrogel serves as an injectable delivery vehicle in colonic 
mucosal wound model. (a) A wound is observed through the camera. (b) The needle is 
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inserted at the distal end of the wound by carefully penetrating the mucosa. (c-d) The 
contents of the custom-made device are injected into the site. (e) The needle is removed. 
The dotted line highlights the wound. Images show a 27-gauge needle (OD: 0.41 mm). All 
experiments with mice were performed while following institutional and national 
guidelines. 
5.6 Example Calculation 
This is an example of calculations needed to prepare hydrogel precursor solutions 
starting with 100 mg of PEG-4MAL macromer, which is used to produce a total of 2.5 mL 
hydrogel volume of 4.0% (wt./vol.), 20 kDa PEG-4MAL hydrogels (G’: 100 Pa) 
functionalized with 2.0 mM RGD and crosslinked with GPQ-W peptide. This volume of 
PEG-4MAL hydrogel is enough for approximately sixty 40 µL-hydrogels for in vitro HO 
encapsulation or approximately fifty 50 µL-hydrogels for in vivo injections of HO-
containing hydrogels, as previously reported for HIO generation and HLO culture127. The 
total volume of hydrogel can be varied based on the total volume and number of hydrogels 
needed for experimentation. As discussed in the Experimental Design section, PEG-4MAL 
macromer size and density, and the type and density of adhesive and crosslinking peptides 
can be varied, providing that all maleimide groups are conjugated, to reach the desired 
biophysical and biochemical matrix properties, respectively. Variations to the biophysical 
and biochemical matrix properties can be explored if the hydrogel formulation described 
here does not support the viability and growth of the human spheroid/HO of interest. In 
this case, this example would serve as a guide of the calculations required to form the 
desired hydrogel. It is important to highlight that changes to the biophysical and 
biochemical matrix properties may change the values used in this example calculation but 
do not change the steps described in this protocol. As shown here, it is essential to consider 
the purity of the peptides and the maleimide substitution efficiency of the PEG-4MAL, 
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provided by the vendors, to achieve complete crosslinking of the hydrogel. The volume 
fractions provided in the example (0.4 for PEG-4MAL and 0.2 for adhesive and 
crosslinking peptides) correspond to the volume ratios described in the protocol (2:1:1, 
PEG-4MAL/adhesive peptide/crosslinking peptide) and are recommended based on 
previous reports9,127. It is recommended to translate this example of calculations into a 
spreadsheet for convenience. 
The specific hydrogel formulation provided in this example was previously 
reported for HIO generation and HLO culture127, and thus serves as a starting point to 
identify a hydrogel formulation for the generation and culture of the HO of interest. 
Table 2: Example calculation. 
MWPEG-4MAL 22000 Da (molecular weight of PEG-4MAL provided by vendor) 
MWRGD 690.6 Da (molecular weight of RGD provided by vendor) 
MWGPQ-W 1704.9 Da (molecular weight of GPQ-W provided by vendor) 
4 maleimide groups per PEG-4MAL macromer 
PPEG-4MAL 0.96 (maleimide substitution efficiency provided by the vendor) 
PRGD 0.85 (RGD fraction concentration provided by vendor) 
PGPQ-W 0.8 (GPQ-W fraction concentration provided by vendor) 
CPEG-4MAL  4.0 %wt./vol. (desired final PEG-4MAL density) 
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CRGD 2.0 mM (desired final adhesive ligand density) 
XPEG-4MAL 0.4 (volume fraction of PEG-4MAL in hydrogel) 
XRGD 0.2 (volume fraction of RGD in hydrogel) 
XGPQ-W 0.2 (volume fraction of GPQ-W in hydrogel) 
 
1. Determine (VPEG-4MAL) the volume needed to reconstitute mPEG-4MAL = 100 mg of 
PEG-4MAL: 
VPEG-4MAL = mPEG-4MAL ∗
XPEG-4MAL
CPEG-4MAL
= 1.0 mL 
2. Determine final molarity of maleimide groups (MMAL) based on mPEG-4MAL and 
VPEG-4MAL: 
MMAL = mPEG-4MAL ∗
4∗XPEG-4MAL∗PPEG-4MAL
MWPEG-4MAL∗VPEG-4MAL
= 6.98 mM 
3. Determine the volume needed to reconstitute the (VRGD) RGD and (VGPQ-W) GPQ-
W: 
VRGD = VPEG-4MAL ∗
XRGD (or XGPQ-W) 
XPEG-4MAl
= VGPQ-W = 0.5 mL 
4. Determine the mass of RGD (mRGD) needed to obtain CRGD: 
mRGD = CRGD ∗
MWRGD∗VRGD
PRGD∗XRGD
= 4.06 mg 
5. Determine the final molarity of free maleimide groups (MMAL-GPQ-W) after 
accounting for maleimide groups reacted with RGD: 
MMAL-GPQ-W = MMAL − CRGD = 4.98 mM 
6. Determine the mass of GPQ-W (mGPQ-W) needed to react with MMAL-GPQ-W:  
mGPQ-W = MMAL-GPQ-W ∗
MWGPQ-W∗VGPQ-W
2∗PGPQ-W∗XGPQ-W




Troubleshooting advice can be found in Table 1. 




Hydrogels do not form Inadequate pH 
adjustment of the 
peptide solutions 
 
Purity level of 









penetration of the 
needle bevel at 
wound site (only 
for step 13B xi) 




Consider the peptide purity provided by 
vendor as shown in Box 1. 
 
Determine peptide purity by UV 





Penetrate the tissue slightly past the 
needle bevel to ensure full delivery of 
hydrogel solution 
 
13 Spheroids do not 














Ensure that the growth factors are freshly 
added 
 
13 Spheroids sink to the 
bottom of the dish and 
fail to develop into 
HOs 
The hydrogel is 
degrading too fast 







too close to the 




Reduce spheroid density per hydrogel 
 






During hydrogel crosslinking, flip the 
plate upside-down to ensure spheroids are 




Low or no HO 
engraftment into host 
tissue 
Gravity settling 
of HOs to one 
end of the syringe 
Shake the syringe gently before each 
injection 
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 Clogging in the tubing 
due to hydrogel 
crosslinking 
Untimely mixing 
of the hydrogel 
precursor 
solutions in the 
tube prior to 
injection 
 
pH is too high 
Verify that there is no leakage from the 






Reduce the pH of the crosslinker solution 
to delay reaction during injection 
Table 3: Troubleshooting table. 
5.7 Anticipated Results 
This protocol outlines the synthesis of PEG-4MAL hydrogels that can generate and 
maintain hPSC-derived HOs starting from hPSC-derived 3D spheroids for multiple 
passages without the need for Matrigel™ encapsulation. Additionally, this synthetic matrix 
can be used as a delivery vehicle to promote HIO engraftment and accelerated wound 
healing of injured colonic tissue127. Intestinal spheroids embedded in the engineered 
hydrogel (Storage modulus (G’): 100 Pa; 4.0%, 20 kDa PEG-4MAL; 2.0 mM RGD; GPQ-
W crosslinker) develop into HIOs with lumens after 4–5 d in culture (Fig. 32a,b). During 
expansion, spheroids change shape and display epithelial budding at the interface with the 
hydrogel (Fig. 32b). Furthermore, hydrogel-generated HIOs can be passaged into fresh 
hydrogels every 7–10 days to support further differentiation of HIOs, demonstrating that 
PEG-4MAL hydrogels can generate and maintain fully-developed HIOs to similar levels 
as Matrigel™ (Fig. 32c,d). We have successfully passaged HIOs for up to 3 passages, 
spanning approximately 21 d, stopping only for an experimental endpoint. It is likely that 
HIOs will continue to grow and expand for a much longer period than the mentioned 21 d. 
Established HIOs grow in size, change shape, maintain a central lumen, and display cell 
outgrowths migrating into the hydrogel (Fig. 32b,c). In Figure 33 we show that cells 
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expressing markers of human cells have engrafted in the host tissue 4 weeks following in 
vivo injection of HIO-containing PEG-4MAL precursor solutions to the colonic mucosal 
wound bed, consistent with our previous study18.  
 
Figure 32: PEG-4MAL hydrogel supports hPSC-derived intestinal spheroid 
development into HIOs. Transmitted light microscopy images of hiPSC-derived HIO 
generated within 4.0% PEG-4MAL-RGD hydrogels after (a) 1 d, (b) 5 d, and (c) 21 d since 
encapsulation. HIO in (c) has undergone two passages before this time-point. Scale bars: 
100 μm (a, b) and 500 μm (c). (d) Fluorescence microscopy image of a HIO taken 21 d 
after encapsulation in 4.0% PEG-4MAL-RGD hydrogel. HIO was labeled for cell-cell 
junctions (β-CATENIN; 1:100; BD biosciences, cat. no. 610153) and proliferative cells 
(KI67; 1:100; Abcam, cat. no. ab15580). DAPI (1:1000), counterstain. “L” indicates HIO 
lumen. Bar, 100 μm. Samples were imaged using an Axiovert 35, Zeiss microscope and 
analyzed with LAS X software (Leica Microsystems, Inc.). 
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Figure 33: PEG-4MAL hydrogel promotes HIO engraftment into mucosal wounds. 
Fluorescence microscopy images of murine colonic tissue at the wound site labeled for 
human cell nuclei (NUMA; 1:100; EMD Millipore, cat. no. MAB1281) taken 4 weeks post-
delivery. DAPI (1:1000), counterstain. Bar, 100 μm. All experiments with mice were 
performed while following institutional and national guidelines. This data is representative 
of the results we saw following injection of hydrogels containing HIO in two independent 
studies (n = 4 mice per condition, 5 injections per mouse).  Further results from this study 
are published127. Samples were imaged using an Axiovert 35, Zeiss microscope and 









CHAPTER 6. CONCLUSIONS AND FUTURE 
CONSIDERATIONS 
This overarching objective of this thesis was to develop an engineered synthetic 
hydrogel matrix that presents independently-tunable basement membrane-like bioactivity 
and mechanical properties that supports different epithelial morphogenetic programs. 
Although naturally-derived materials have been extensively used to recapitulate epithelial 
morphogenesis, they are inherently limited by lot-to-lot compositional and structural 
variability, and the inability to decouple biochemical and biomechanical properties. 
Additionally, in the case of MatrigelTM, its tumor-derived nature limits its translational 
potential. We have demonstrated that the fully defined, synthetic PEG-4MAL hydrogel 
platform allows the study of the independent contributions of ECM properties to different 
epithelial morphogenetic programs, and supports epithelial cell survival, proliferation, 
polarization, and assembly into 3D multicellular structures, recapitulating different 
epithelial morphogenesis program. Additionally, this synthetic material has the capacity to 
present adhesive peptides and protease-degradable crosslinks that support cell functions 
and promote cell engraftment in vivo. 
In Aim 1, we developed a PEG-4MAL hydrogel that supports robust and highly 
reproducible in vitro growth and expansion of hPSC-derived human intestinal organoids 
such that 3D structures are never embedded in tumor-derived ECM. Both mechanical and 
biochemical properties of the synthetic ECM were important to intestinal organoid 
formation, and we identified an optimal formulation that supports intestinal spheroid 
survival, expansion and epithelial differentiation into HIOs and differentiation into mature 
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intestinal tissue in vivo to similar levels as MatrigelTM. Additionally, we showed that this 
synthetic matrix supports the development of other human organoids such as HLOs. We 
also demonstrated that the hydrogel serves as an injectable HIO vehicle that can be 
delivered into injured intestinal mucosa resulting in HIO engraftment and improved colonic 
wound repair. 
In Aim 2, we engineered a PEG-4MAL hydrogel with independent control over 
proteolytic degradation, mechanical properties, and adhesive ligand type and density to 
study the impact of ECM properties on epithelial tubulogenesis program. We showed that 
sensitivity of the synthetic material to membrane-type matrix metalloproteinase-1 (MT1-
MMP) was required for epithelial tubulogenesis. Additionally, a narrow range of matrix 
elasticity, presentation of specific adhesive ligand type, and a threshold level of adhesive 
ligand density of the MT1-MMP-sensitive hydrogel were important to direct epithelial 
tubulogenesis. Finally, we demonstrated that the engineered PEG-4MAL hydrogel 
supported organization of epithelial tubules that displayed lumen formation, polarization 
and secreted ECM components. The PEG-4MAL hydrogel serves as a platform to 
recapitulate epithelial tubular morphogenetic programs and to characterize the independent 
contributions of the matrix properties to distinctive normal or abnormal epithelial 
phenotypes. 
Together, these studies establish PEG-4MAL hydrogel as a platform to study the 
independent contributions of the matrix properties to different epithelial morphogenetic 
programs. Additionally, we demonstrated that PEG-4MAL hydrogels can be used as a cell 
delivery vehicle that may be used therapeutically to treat intestinal injury, overcoming the 
limitations of natural materials. Nevertheless, translation of this technology to the human 
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scale will require significantly more validation. This will include evaluation of the cell 
delivery efficacy in larger animal models of epithelial injury. The synthetic, well defined 
composition of the material may increase the probability of successful scaling. Each 
component can be synthesized in scalable amounts at very high purity, which allows for 
consistent and repeatable material synthesis. However, an important consideration of this 
engineered hydrogel platform is its rapid reaction kinetics that may result, if mixing is not 
conducted properly, in the formation of an inhomogeneous gel that presents variabilities in 
its physicochemical properties. Therefore, to avoid inhomogeneities in the hydrogel 
properties due to premature crosslinking, the functionalized macromer and crosslinker 
solutions may need to be delivered separately and mixed at the in vivo delivery site, or 
mixed prior to rapid delivery into the in vivo site.  
Although the studies discussed in this thesis have developed novel artificial 
hydrogel matrices that present BM-like properties, several challenges need to be addressed 
to continue engineering synthetic matrices that recapitulate and direct complex cellular 
processes. For instance, there is a need for hydrogels that can recapitulate the in vivo 
microenvironment by presentation of multiple adhesive ligand types at specific densities 
that can orchestrate complex cellular responses. Such artificial matrix designs are 
important for the support of complex cellular systems (e.g. primary and stem cells) that 
still represent a challenge due to their increased sensitivity, and to further direct innate 
cellular functions. Furthermore, as different studies have demonstrated successful 
recapitulation of complex epithelial morphogenetic programs using Matrigel™, future 
developments of BM-like synthetic hydrogels should move towards designing hydrogels 
that recapitulate mechanical and structural (e.g., fibrillar structure) properties of Matrigel™ 
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and collagen gels. Therefore, as new ways of integrating bioactivity into hydrogel matrices 
are designed, novel engineered synthetic materials will continue to offer new developments 
in regenerative medicine and tissue engineering fields, and promise innovative therapeutic 
options that naturally derived materials cannot provide. 
Overall, the engineered PEG-4MAL hydrogel systems developed here begin to 
address the need for modular synthetic organotypic in vitro culture materials that recreate 
the epithelial morphogenetic developmental programs, and can be used to study the 
independent contributions of the matrix properties to epithelial morphogenesis. Finally, 
these data show our simple, injectable, biomaterial based delivery carrier outperforms 
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